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Endogenous cannabinoids are lipid-based ligands of the main cannabinoid receptors type 1 and 2 
(CB1R and CB2R). In contrast to the well-studied effects of CB1Rs, much less is known about the 
physiological role of CB2Rs in the central nervous system (CNS). In fact, CB2Rs were considered as 
peripheral cannabinoid receptors representing the complementary cannabinoid receptor to the CB1R 
in the CNS. However recent pharmacological, behavioral and genetic studies have determined the 
presence of functional CB2Rs in the brain and their involvement in various physiological and 
pathological conditions. Endocannabinoids are produced in an activity-dependent manner. Next to 
their well-described role as retrograde modulators of synaptic transmission, endocannabinoids also 
mediate a cell-autonomous slow self-inhibition (SSI). Action potential-driven endocannabinoid 
production followed by binding to cannabinoid receptors induces a long-lasting hyperpolarization of 
the membrane potential, rendering the cell less excitable. Several studies described different 
endocannabinoid receptors and cellular mechanisms by which SSI is implemented in different cell 
types and brain areas: While pyramidal cells and interneurons in the somatosensory cortex were 
reported to mediate SSI via CB1Rs and G protein-coupled inward rectifying K
+ (GIRK) channels, 
hippocampal principal cells were shown to mediate SSI in a CB2R mediated and input-resistance-
independent manner. However, the molecular mechanism by which the long-lasting 
hyperpolarization is implemented was not clear. During my thesis I was part of a team that 
demonstrated that hippocampal SSI is mediated via activation of the Na+/bicarbonate cotransporter. 
In order to get further insight in the occurrence of SSI in different classes of neurons, we analyzed the 
presence of SSI in one type of hippocampal interneuron and showed that oriens-lacunosum 
moleculare (OLM) interneurons do not express SSI. Further, we investigate SSI in different neuron 
types of layer 2/3 in the primary somatosensory cortex and show that regular firing cells express SSI 
in contrast to fast-spiking interneurons. Trains of action potentials induced a long-lasting 
hyperpolarization that was accompanied by a change in input resistance due to GIRK channel 
activation. By using cannabinoid receptor-specific pharmacology as well as transgenic mice lacking 
either CB1Rs or CB2Rs, we demonstrate that this effect is mediated by CB2R activation.  
Taken together, hippocampal and cortical SSI both represent a CB2R-dependent mechanism; 
however the underlying mechanism by which the hyperpolarization is implemented differs between 
the different brain regions. By describing an additional cellular mechanism for SSI induction, these 
findings add further insights on the physiological role of CB2Rs and expand our knowledge about cell 
type-specific differential cannabinoid signaling. Moreover, these findings suggest CB2Rs as a 




Endogene Cannabinoide sind bioaktive Lipide, die an die Cannabinoid Rezeptoren Typ 1 und 2 (CB1R 
und CB2R) binden. Im Gegensatz zum CB1R, ist weitaus weniger über die physiologische Rolle der 
CB2R im zentralen Nervensystem (ZNS) bekannt. CB2R wurden auch als Cannabinoid Rezeptoren der 
periphären Region angesehen, komplementär zu den CB1R im ZNS. Jedoch haben zahlreiche 
pharmakologische, genetische und Verhaltensstudien in den letzten Jahren immer mehr Hinweise 
geliefert, die das Vorkommen von funktionalen CB2R auch im Gehirn zeigen und ihre Funktion in 
physiologischen und pathologischen Prozessen belegen.  
Endocannabinoide werden aktivitätsabhängig gebildet. Die meisten bisher untersuchten neuronalen 
Endocannabinoid vermittelten Effekte beschreiben deren Aktivität als retrograde Signalmoleküle, die 
die synaptische Transmission modulieren. Zusätzlich wurde gezeigt, dass einige Zellen eine 
zellautonome Form der Selbstinhibierung (slow self-inhibition, SSI) aufweisen, bei der 
Endocannabinoide eine tragende Rolle spielen. Diese Zellen zeigen eine Aktionspotential getriebene 
Produktion von Endocannabinoiden, welche anschließend Cannabinoidrezeptoren an derselben Zelle 
aktivieren und dadurch eine Hyperpolarisierung des Membranpotentials zur Folge haben. Dabei 
wurden unterschiedliche zelluläre Mechanismen, aber auch unterschiedliche Cannabinoidrezeptoren 
beschrieben, die diesen Effekt hervorrufen. Während in Pyramidenzellen und Interneuronen des 
somatosensorischen Cortexes eine Aktivierung von CB1R K
+-Kanäle (GIRK) erregen, ist in 
Pyramidenzellen des Hippocampus eine Aktivierung von CB2R erforderlich, um SSI zu induzieren, die 
keine Änderung des Eingangswiderstandes zur Folge hat. Allerdings war der zelluläre Mechanismus, 
mit welchem die Hyperpolarisierung im Hippocampus implementiert wird, noch unbekannt. In dieser 
Arbeit zeigen wir, dass SSI in Pyramidenzellen des Hippocampus durch Aktivierung des Na+-
Bikarbonat Transporters hervorgerufen wird und dass dieser Effekt in einer Gruppe von 
hippocampalen Interneuronen nicht vorhanden ist. 
Desweiteren untersuchen wir SSI in verschiedenen Zelltypen der Schicht 2/3 des somatosensorischen 
Cortexes und konnten zeigen, dass die langanhaltende Hyperpolarisierung in regulär feuernden 
Zellen auslösbar ist während schnell feuernde Interneurone kein SSI aufweisen. Wiederholtes 
Auslösen von Aktionspotentialen führt zu einer langanhaltenden Hyperpolarisierung des 
Membranpotentials, die mit einer Änderung des Eingangswiderstandes einhergeht. Diese wird durch 
Aktivierung von GIRK-Kanälen hervorgerufen. Mithilfe von pharmakologischen Interventionen und 
transgenen Knockout-Mäusen, die kein CB1R oder CB2R expremieren, zeigen, dass dieser Effekt durch 
CB2R Aktivierung initiiert wird. 
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Zusammenfassend zeigt diese Arbeit, dass SSI im Hippocampus sowie im Cortex durch CB2R 
Aktivierung ausgelöst wird. Die zellulären Mechanismen, die für die Hyperpolarisierung eine Rolle 
spielen unterscheiden sich jedoch in den beiden Gehirnregionen. Dies beschreibt einen weiteren 
CB2R vermittelten Effekt und erweitert das Verständnis der physiologischen Bedeutung von CB2R im 
ZNS zu erweitern. Zusätzlich heben diese Befunde die Bedeutung von CB2R und das Potential ihrer 
Manipulation als Grundlage für therapeutische Behandlungen hervor.  
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1.1 History of cannabinoids 
Cannabinoids represent a class of chemical compounds that act on cannabinoid receptors. These 
substances were initially found in Cannabis Sativa, a plant that has been cultivated throughout 
recorded history (Clarke and Merlin, 2017). Cannabis originated in South and Central Asia and was 
cultivated for fiber, seed and resin production. Subsequently, cannabis was traded to different 
cultures to reach cosmopolitan distribution while diverse species of cannabis evolved since different 
parts of the plants were traditionally used for particular purposes: While European and East Asian 
societies mainly used cannabis for its strong fibers and nutritious seeds, African, Middle Eastern and 
South Asian cultures used it to a higher extend for its psychoactive properties. The latter caused 
recreational, religious and medical use of cannabis (Pain 2015). The earliest traceable use of cannabis 
as medicine is attributed to the Chinese Emperor Shen-Nung at around 2700 BC, where it was used 
as a treatment for different maladies including rheumatic pain, intestinal constipation and malaria 
(Zuardi, 2006). Around 1000 BC, cannabis was widely used in India for religious and medical 
purposes: It was used inter alia as analgesic, anticonvulsant, hypnotic, tranquilizer, anesthetic, 
antibiotic and appetite stimulant (Zuardi, 2006). In the Assyrian Empire (800 BC), cannabis fumes 
were prescribed as a treatment for symptoms of depression and arthritis (Mechoulam and Hanus, 
2001). A Greek physician, Padacius Discodires, described in the first century AD the benefits of 
Cannabis seed’s juice in the treatment of earache in De Materia Medica, an encyclopedia about 
herbal medicine (Figure 1A). 
The introduction of cannabis in the Western medicine occurred in the 19th century and numerous 
scientific articles describing its effects were published in this time. William B. O’Shaugnessy described 
in his book ‘On the preparation of the Indian hemp, or gunjah’ several human experiments for 
treatment of rheumatism, convulsions, migraines, inflammation, cholera and muscular spasms of 
tetanus and rabies (Mechoulam and Hanus, 2001; Zuardi, 2006). Jacques-Joseph Moreau de Tours 
was rather interested in the psychoactive effects of cannabis (Moreau de Tours, 1845). He tested 
different cannabis preparations for the treatment for depression and anxiety and proposed its use in 
melancholia. His idea of the potential in psychoactive substances for treating mental illnesses is seen 
as the origin of experimental psychiatry and psychopharmacology (Fankhauser, 2008; Pacher and 
Mechoulam, 2011). In the late 19th century, cannabis extracts or tinctures were produced and 
marketed by  several companies (Figure 1B). The medical indication of cannabis by that time was 
summarized in Sajou’s Analytic Cyclopedia of Practical Medicine (1924) as 1) sedative or hypnotic, 2) 
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analgesic and 3) other uses (including: Improve appetite and digestion, diarrhea, cholera, diabetis 
mellitus). 
In 1895, Wood and his colleagues were able to identify and isolate the first cannabinoid: Cannabinol 
(CBN; Wood et al., 1896), whose structure was identified 40 years later (Cahn, 1933). Shortly after, a 
second phyto-cannabinoid, cannabidiol was independently isolated and identified by the laboratories 
of Adams and Todd (Adams et al., 1940; Jacob and Todd, 1940) and its chemical structure was fully 
established by Raphael Mechoulam (Mechoulam and Shvo, 1963). It was also Raphael Mechoulam, 
who isolated and identified the structure of tetrahydrocannabinol (THC; chemical name (−)-trans-Δ⁹-
tetrahydrocannabinol), the major psychoactive compound of cannabis (Gaoni and Mechoulam, 
1964), which initiated the start of modern cannabinoid research. From now on, it was possible to 
investigate the effects of individual cannabinoids by direct administration, instead of using infusions 
or extracts of cannabis plants, which often varied in their cannabinoid compositions and content. In 
the following years various publications demonstrated the potential of cannabinoids, especially of 
THC, as a therapeutic agent for several conditions. These finding led to the discovery of the 
endocannabinoid system (see chapter 1.2). Until today almost 150 different phytocannabinoids have 
been described, exhibiting varied effects (Hanus et al., 2016). In addition, a plethora of synthetic 
cannabinoids were developed that show diverse properties including increased potency or selectivity 
towards specific cannabinoid receptors. This enabled more detailed research on the role of the 
cannabinoid system in physiology and disease.  
 
 
Figure 1: Cannabis Sativa.  
A: Illustration from the Vienna Dioscorides, 
512 AD, illustrated manuscript of De Materia 
Medica by Dioscorides. B: Advertisement by 
the company E. Merck (Darmstadt, Germany) 




1.2 Endocannabinoid system 
The endocannabinoid system consists of the endogenously produced lipid-based signaling molecules 
known as endocannabinoids, the enzymes required for synthesis and degradation of the 
endocannabinoids, as well as the endocannabinoid receptors. It represents one of the main 
modulatory systems and is expressed in vertebrates and various clades of invertebrates including 
nematodes, mussels, leeches, crustaceans and even in the most primitive animal with a nervous 
system, the Hydra (McPartland et al., 2006). Due to a secondary loss during evolution, cannabinoid 
receptors are absent in insects (McPartland et al., 2001).  
The discovery and characterization of cannabinoid receptor type 1 (CB1R) marked the beginning of 
the identification of the endocannabinoid system. A radiolabeled synthetic cannabinoid was found to 
bind cell membranes from the rat brain in a specific and selective manner exhibiting characteristic 
features of receptor binding (Devane et al., 1988). Shortly after this discovery, the CB1R was cloned 
from rat and human brain (Gerard et al., 1990; Matsuda et al., 1990). It has been proposed that CB1R 
expression is mainly limited to the CNS (Herkenham et al., 1990) and it was not clear how the non-
psychoactive effects of cannabis were mediated, until the CB2R was identified and cloned (Munro et 
al., 1993). By this time it was proposed that CB2Rs are only expressed in the periphery and not in the 
CNS (Buckley et al., 2000; Munro et al., 1993). Meanwhile, endogenously produced ligands of 
cannabinoid receptors were identified: Anandamide (AEA, chemical name: N-
Arachidonylethanolamide; Devane et al., 1992) and 2-arachnidonyl glycerol (2-AG; Mechoulam et al., 
1995; Sugiura et al. 1995). These two ligands are regarded as the two major endocannabinoids. 
 
1.2.1 Cannabinoid receptors 
1.2.1.1 CB1R 
CB1Rs are among the most widely expressed G protein-coupled receptors (GPCRs) in the brain (Figure 
3C). As characteristic for GPCRs, CB1Rs possess seven transmembrane domains with extracellular N-
terminus and intracellular C-terminus. Extracellular ligand binding leads to activation of the GPCR 
associated with conformational change of the receptor. This causes the exchange of Guanosine 
diphosphate (GDP) to Guanisine triphosphate (GTP) at the G-subunit of the G protein. This 
exchange triggers dissociation of the G-subunit and the G-subunit from the receptor. Both G 
and G act as second messengers and activate different transduction pathways while the receptor is 
able to activate the next G protein. G protein signaling is terminated by the hydrolysis of GTP by the 
G-subunit and reassociation of G and GPCR to G(Wettschureck and Offermanns, 2005).  
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Different types of G-subunits were categorized based on their downstream transduction target: 
Gs, Gi/o, Gq/11 and G12/13. Gs and Gi/o subunits influence the cyclic adenosine monophosphate 
(cAMP)-dependent transduction pathway by stimulating or inhibiting the cAMP-producing enzyme 
adenylate cyclase (AC), respectively. Increased cAMP can activate cyclic nucleotide-gated ion 
channels and protein kinase A (PKA), which in turn phosphorylates a number of other proteins 
including transcription factors. Further, activation of Gi/o can activate the mitogen-activated protein 
kinase (MAPK) pathway generating diverse responses including cell proliferation, differentiation, 
migration and apoptosis. Gq/11 activates the phospholipase CPLC) pathway resulting in an 
increase of the second messengers inositol (1,4,5) triphospate (IP3) and diacylglycerol (DAG). IP3 acts 
on IP3 receptors in the endoplasmatic reticulum (ER) resulting in an intracellular Ca
2+ increase from 
ER-stores. While IP3 diffuses into the cytosol, DAG remains in the plasmamembrane acting as a 
physiological activator of protein kinase C (PKC) that is involved in regulation of a variety of enzymes. 
DAG further serves as a precursor of the endocannabinoid 2-AG. The effectors of the G12/13 pathway 
are RhoGEF (Rho-guanine nucleotide exchange factors) which in turn can activate various proteins 
responsible for regulation of the cytoskeleton (for more information on G protein-signaling please 
see the reviews by: Hilger et al., 2018, Gurevich and Gurevich, 2017, Wettschureck and Offermanns, 
2005). 
The interaction with various intracellular signaling proteins does not only affect the cell-specific 
signaling cascade after activation of GPCRs, but may also influences receptor confirmation, which can 
lead to modified agonist binding properties (DeVree et al., 2016). On the other hand, the structure of 
the agonist influences binding kinetics and activation degree of the receptor, meaning that different 
agonists can give rise to different cellular responses in the same tissue due to different binding 
kinetics and stabilization of different receptor confirmations (Ibsen et al., 2017). This concept is 
called functional selectivity or biased signaling (Figure 2).  
Agonist binding to CB1Rs induces activation of several second messenger cascades primarily via 
pertussis toxin sensitive activation of Gi/o protein signaling. However, coupling to Gs was also 
reported under certain conditions. Additionally, ligand binding to CB1Rs was shown to evoke Ca
2+ 
transients that were PLC dependent and mediated by Gi/o or Gq/11 proteins (Sugiura et al., 1997). 
Further, CB1R activation modulates various types of ion channels by direct interaction of the G 
subunit: Activation of A-type K+ channels and G protein coupled inward rectifying K+ (GIRK) channels; 




Next to G protein-mediated signaling, another form of GPCR-signaling is the arrestin mediated 
pathway that is activated by binding of arrestin to the phosphorylated receptor. In order to prevent 
excessive signaling or to adapt to persistent stimulation, GPCR to G protein coupling can be inhibited 
by arrestins in a process called desensitization (Smith and Rajagopal, 2016). Besides receptor 
desensitization, arrestin promotes regulation of signal transduction, receptor trafficking and arrestin-
mediated signaling. After binding arrestin acts as a scaffolding protein for different signaling 
pathways including extracellular signal-regulated kinases (ERK). CB1R activation can lead to a direct 
recruitment of -arrestin which induces endocytosis of the receptor leading to CB1R removal from 
the plasma membrane (Ibsen et al., 2017). In addition, several CB1R agonists display biased agonism: 
WIN55,212,2, CP55,940, THC, 2-AG and N-arachnidonoyl dopamine (NADA). Remarkably, the 
endocannabinoid NADA represents a highly biased CB1R agonist that is able to induce Ca
2+ influx from 
intracellular Ca2+ stores and slow internalization of CB1Rs but has no effect on AC activity, GIRK 
channels or phosphorylation of ERK (Ibsen et al., 2017). 
 
  
Figure 2: Schematic illustration of characteristic CB1Rs signaling.  
CB1R typically signal via the Gi/o pathway. However, different agonists can display biased agonism 
towards one intracellular pathway over another. Biased agonist 1 shows a stronger activation of G 
protein-associated signaling pathways, while biased agonist 2 rather activates the -arrestin 
pathway. Adapted from Ibsen et al., 2017. 
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The crystal structure of human CB1R was recently identified, revealing insights into the activation 
mechanism of agonist and antagonist binding to the receptor (Figure 3A; Hua et al., 2017; Hua et al., 
2016; Shao et al., 2016). The suggestion that CB1Rs possess distinct but overlapping binding sites for 
the agonists WIN,55,212-2 and CP55,940 (Song and Bonner, 1996b) was supported by analysis of 
agonist docking in the crystal structure. In addition, a variety of allosteric modulators of CB1Rs were 
identified that do not or only partially interact with the orthosteric binding sites where endogenous 
cannabinoids bind (Saleh et al., 2018). The development and optimization of allosteric modulators for 




Figure 3: Crystal structure and expression of cannabinoid receptors.  
A: Crystal structure of agonist- (orange) and antagonist-bound (blue) human CB1R (Hua et al., 2017; Li 
et al., 2019). B: Crystal structure of antagonist-bound human CB2R. Modified from Li et al., 2019. C: 
Autoradiography of [3H]CP55,940 binding in rat brain; Cx: Cortex; Hi: Hippocampus, Th: Thalamus; 
CP: Caudate putamen, GP: Globus pallidus, Ep: Entopeduncular nucleus, Col: Colliculi, SNr: Substantia 
nigra, Cer: Cerebellum, BrSt: Brainstem. Modified from Herkenham et al., 1990.  
 
CB1Rs are encoded by the gene CNR1 located on mouse chromosome 4 and human chromosome 6 
and consists of 473 amino acids in rodents and 472 amino acids in human, showing 97-99% sequence 
identity among these species (Chakrabarti et al., 1995; Gerard et al., 1990; Matsuda et al., 1990). In 
addition, two alternative splice variants of the CB1R were discovered: CB1Ra and CB1Rb (Ryberg et al., 
2005; Shire et al., 1995). These variants possess a shortened N-terminal, show altered ligand binding 
and are expressed at low levels in a variety of tissues (Ryberg et al., 2005).  
Since the discovery and first distribution analysis of CB1R expression using radiolabeled ligands 
(Devane et al., 1988; Herkenham et al., 1990; Figure 3C) much progress was achieved in 
characterizing expression patterns of CB1R in neuronal tissues. Soon after the first description, CB1R 
cDNA was cloned, leading to investigation of regional and cellular distribution of CB1R mRNA by in 
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situ hybridization (Mailleux and Vanderhaeghen, 1992; Matsuda et al., 1993). The development of 
specific antibodies shed further light on the subcellular and cell type-specific distribution of CB1R via 
immunohistochemical and electron microscopy-based methods (Katona et al., 1999; Tsou et al., 
1998). A meta-analysis study on 119 autoradiographic, immunohistochemical and in situ 
hybridization studies summarized the distribution of CB1R expression in human and rat brain 
(McPartland et al., 2007). CB1Rs are highly expressed in the basal ganglia nuclei, hippocampus, cortex 
and cerebellum. In fact, its distribution correlates with the role of the cannabinoid system in the 
control of motor function, memory and analgesia. In addition, species-dependent differences in the 
expression levels were observed: CB1R density was higher in cognitive regions (cerebral cortex) in 
human, while rat brains showed a higher expression in movement-associated areas (cerebellum, 
caudate-putamen; McPartland et al., 2007). Interestingly, two different patterns of CB1R mRNA 
distribution were found: In some regions, like the cerebellum or the thalamus, almost all cells express 
CB1R. In contrast, in the hippocampus or the cerebral cortex only few neurons express very high 
levels of CB1R (Mailleux and Vanderhaeghen, 1992; Matsuda et al., 1993). These findings were 
supported by immunohistochemical studies detecting strong CB1R expression in cholecystokinin-
positive interneurons, low expression in excitatory cells and no CB1R in parvalbumin-positiv 
interneurons (Katona et al., 1999; Tsou et al., 1999). However, some discrepancies were described 
between mRNA expression detected by in situ hybridization and protein expression detected by 
autoradiography or immunohistochemistry. This discrepancy can be explained by the predominant 
presynaptic location of CB1Rs (Katona et al., 1999) detected by autoradiography and 
immunohistochemistry, while in situ hybridization stained the perikarya. Further, astroglial cells were 
shown to express functional CB1Rs (Han et al., 2012; Navarrete and Araque, 2008). 
In addition to the presynaptic location of CB1Rs, several studies indicate the presence of functional 
CB1Rs on different intracellular locations including endosomes, lysosomes (Grimsey et al., 2010) and 
mitochondira (Benard et al., 2012). Further, CB1Rs were found in the postsynaptic density and the 
extrasynaptic membrane of striatal neurons (Kofalvi et al., 2005). Postsynaptic expression was also 
found in superficial Cornu Ammonis 1 (CA1) pyramidal neurons (Maroso et al., 2016). 
 
1.2.1.2 CB2R 
The CB2R is encoded by the gene CNR2 and shares only 44% sequence homology with CB1R at protein 
level. CB2Rs has a greater species differences between rodents and humans compared to CB1Rs (82% 
similarity; 360 amino acids in human, 347 amino acids in mice; Kano et al., 2009). In rats four 
different specific mRNA isoforms were identified (Zhang et al., 2015). In addition, higher level of CB2R 
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mRNA was detected in mice in different brain regions and cell types, compared to rats (Zhang et al., 
2015).  
In contrast to the extensively studied CB1R, much less is known about the role of CB2Rs in the CNS. 
Since the discovery and cloning of the CB2R cDNA (Munro et al., 1993) it was considered to represent 
the “non-neuronal” counterpart of the “neuronal” CB1R (Buckley, 2008). CB2Rs were mainly detected 
in immune cells, including macrophages, B-cells, T-cells as well as microglia, while initially no signal 
could be detected in the brain (Munro et al., 1993). Further, autoradiography studies using a high 
affinity CB1/CB2R agonist showed no signal in the brain of CB1R knockout (KO) mice, whereas a strong 
labeling was present in the spleen indicating CB2R expression (Buckley et al., 2000; Zimmer et al., 
1999). A transgenic reporter mouse expressing GFP under the CB2R promoter supported the finding 
that CB2Rs are only present in peripheral tissue and that the major source for GFP-signal in the brain 
arises from microglia (Schmole et al., 2015). However, the dogma of CB1R-complementary, strictly 
non-neuronal CB2R expression was challenged by several studies that showed expression of CB2Rs 
and its mRNA in various brain regions using different methods (immunohistochemistry: Gong et al., 
2006; Zhang et al., 2014; in situ hybridization: Li and Kim, 2015; Stempel et al., 2016; Zhang et al., 
2014; Western blots: Zhang et al., 2019; quantitative real-time polymerase chain reaction: Onaivi, 
2006; Onaivi et al., 2008). However, the interpretation of the detected CB2R signals was often 
questioned, mainly for two reasons: First, adequate CB2R KO controls were not performed or 
generated an unspecific signal. The two available CB2R KO mouse lines (Buckley et al., 2000; Li and 
Kim, 2016) represent partial KOs expressing remaining residues of a non-functional truncated CB2Rs. 
Second, due to the remaining CB2R parts in KO mice, and due to the use of anti-rat CB2R antibodies in 
mice, many commercially available antibodies generate false-positive signals in KO trains (Zhang et 
al., 2019). These methodological obstacles may explain the discrepancies of the former studies. 
However, in addition to the expression analysis of CB2Rs, various behavioral and electrophysiological 
studies support the expression of functional CB2Rs in neuronal cells (see chapter 1.2.3). 
Like the CB1R, CB2R is a classical GPCR. Although both receptors share similar intracellular 
transduction pathways, being most often coupled to Gi/o, several signal transduction pathways that 
have been characterized for CB1R have not been identified for CB2Rs: In rare cases CB1Rs were shown 
to couple to Gs whereas CB2Rs did not (Kano et al., 2009). Controversial findings were published for 
G mediated modulation of ion channels: While earlier publications showed a lack of GIRK and P/Q-
type channel modulation by CB2Rs (Felder et al., 1995), more recent findings demonstrated that 
mouse and human CB2Rs can modulate these ion channels. However, their activation strongly 
depends on the used ligand, representing an example of biased agonism (Atwood et al., 2012b; 
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Soethoudt et al., 2017). Similar to other GPCRs, various CB2R agonists were identified that, upon 
binding to the receptor, favor one transduction pathway over another. A recent study profiled the 
most widely used CB2R ligands and characterized the ability of certain agonist to activate distinct 
signaling pathways and to cause off-target effects (Soethoudt et al., 2017). The authors recommend 
the compounds HU-308, HU-910 and JWH133 as selective CB2R agonists to study the role of CB2Rs in 
biological processes.  
Very recently, the crystal structure of antagonist bound CB2Rs (Figure 3B) was published and revealed 
a distinct, smaller antagonist-binding pocket compared to CB1Rs (Figure 3A). In fact, this antagonist-
binding pocket is similar with regard to size and ligand-interacting residues to the CB1R agonist-
binding pocket, resulting in a conformational similarity of antagonist-bound CB2Rs with agonist 
bound CB1Rs (Li et al., 2019). This study suggests opposing effects of CB1R and CB2Rs and provides the 
explanation for the experimental finding that CB2R antagonists can act as agonists on CB1Rs (Li et al., 
2019). 
 
1.2.1.3 Other targets of endocannabinoids 
Next to the two main cannabinoid receptors CB1R and CB2R, several orphan receptors (receptor 
whose endogenous ligand has not yet been identified) have been postulated to be putative 
cannabinoid receptors. The most promising candidate to represent an additional cannabinoid 
receptor is GPR55: Despite a low sequence homology to CB1R and CB2Rs (13.5% and 14.4%, 
respectively) a variety of synthetic, phyto- and endocannabinoids were shown to activate GPR55, 
including 2-AG and AEA. Although many controversial findings were reported, most studies showed 
that GPR55 cannot be activated by WIN55,212,2, a synthetic CB1R/CB2R agonist. The endogenous 
lipids lysophosphatidylinositol (LPI) and 2-arachidonoyl lysophosphatidyl inositol (2-ALPI) have been 
proposed as endogenous agonists of GPR55. In fact, GPR55 has been also been named LPI1 receptor 
(Kihara et al., 2014; Oka et al., 2007). 
GPR18 is also considered to be associated with the endocannabinoid system, even though it displays 
an even smaller sequence homology to CB1Rs and CB2Rs (13% and 8%, respectively) compared to 
GPR55. Next to metastatic melanomas, as well as gastrointestinal and testicular tissues, GPR18 
expression was found in neurons in various brain regions and in microglia (McHugh, 2012). The 
endocannabinoid N-arachnidonylglycerine has been suggested to be the endogenous GPR18 ligand 
and several reports have indicated this receptor as a therapeutic target in the treatment of different 
pathologies including cancer and intraocular pressure (Morales and Reggio, 2017). 
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Further, it is well established that the endocannabinoids AEA, N-arachidonoyl dopamine (NADA; 
Huang et al., 2002) and noladin ether (Duncan et al., 2004) but not 2-AG, bind to transient receptor 
potential vanilloid 1 (TRPV1) channels at the same binding site as capsaicin, where they act as 
agonists (Pertwee et al., 2010).  
Most GPCRs form homo- or heterodimers to represent their functional structure and both CB1R and 
CB2Rs have been shown to dimerize. When coexpressed with other GPCRs, formation of 
heterodimers can lead to crosstalk between cannabinoid and non-cannabinoid receptors connecting 
both endogenous systems. For example µ-opioid receptor/CB1R heterodimers (Hojo et al., 2008) and 
CB2R/chemokine receptor 4 heterodimers (Coke et al., 2016) were identified in which activation of 
the individual monomers influenced the function of the other component. Moreover, GPR55 were 
also shown to form functional dimers with CB1Rs or CB2Rs, which are present in neurons and in 
astrocytes (Kargl et al., 2012; Garcia-Gutierrez et al., 2018). CB1R/CB2R heterodimers were detected 
in rat brain pineal gland, nucleus accumbens and globus pallidus. Although the physiological function 
of such dimers is not known yet, it was showen that antagonization of one monomer blocks agonist 
activation of the other (Callen et al., 2012). Thus, the pharmacological properties of the heterodimers 
can be distinct from those of either one of the homodimeric receptors. 
In addition, endogenous cannabinoid receptor ligands directly interact with several signaling proteins 
in a cannabinoid receptor-independent manner. These targets include GPCRs (muscarinic M1 and M3 
receptors, adenosine receptor A3, serotonergic 5-HT1 and 5-HT2 receptors), ligand gated ion channels 
(serotonergic 5-HT3 receptors, nicotinic acetylcholine receptors, glycine receptors, N-methyl-D-
aspartate sensitive glutamate (NMDA) receptors), voltage gated Ca2+ channels (T-type CaV3 channels) 
and K+ channels (ATP-sensitive inward rectifier channels, voltage gated K+ channels and Ca2+ activated 
K+ channels; reviewed by Pertwee, 2015). 
 
1.2.2 Endocannabinoids 
Endocannabinoids are bioactive lipid messenger molecules that bind to cannabinoid receptors. Their 
lipophilic properties lead to a poor solvability in the hydrophilic extracellular space suggesting local 
and location-dependent activity. Mainly in vitro studies provided evidence that there are at least 15 
endogenous compounds that target cannabinoid receptors either orthosterically (12 compounds) or 
allostherically (3 compounds). Here I describe the five most prominent and so far best studied 





The first endocannabinoid AEA was isolated from pig brain in 1992 and was named ‘anandamide’ 
based on the Sanskrit word ananda that means ‘bliss’ (Devane et al., 1992). Shortly after its 
discovery, activity dependent production of AEA was shown in cultured neurons (Di Marzo et al., 
1994). High frequency stimulation in acute hypothalamic slices induced an increase in AEA levels that 
was abolished by blocking glutamate signaling (Di et al., 2005).  
AEA behaves as a partial agonist to both CB1Rs and CB2Rs whereas it acts as a full agonist and 
represents the endogenous ligand for TRPV1 channels (Pertwee et al., 2010). Synthesis of AEA is 
considered to occur by multiple complementary and compensatory pathways, varying among brain 
regions. Different pathways may be favored for distinct physiological and pathophysiological 
processes. The classical AEA production underlies the metabolism of N-arachidonoyl 
phosphatidylethanolamines (NAPE), which is synthesized from phosphatidyl-ethanolamines (PE) by 
N-acyltransferase (NAT) that is activated by PKA. In addition, NAT activity was shown to be strongly 
stimulated by Ca2+ and it is thought to be the rate-limiting step in AEA production. Hydrolysis of NAPE 
by a NAPE-specific phospholipase D (NAPE-PLD, Figure 4A) represents the major pathway for AEA 
production. However, different effects on AEA levels were reported in NAPE-PLD KO mice and NAPE-
PLD distribution only partially overlaps with CB1R distribution, indicating the presence of additional 
metabolic pathways involved in AEA synthesis (Lu and Mackie, 2016). The best-studied alternative 
pathway describes the cleavage of the NAPE phosphodiester bond by NAPE-selective phospholipase 
C (NAPE-PLC) followed by dephosphorylation to deliberate AEA (Figure 4A). As an additional pathway 
it was shown that -deacylation of NAPE by /domain hydrolase 4 (ABHD4) leads to the formation 
of lyso-NAPE that in turn can either be further deacetylized (by ABHD4) to form glycerophospho (GP)-
AEA followed by phosphodiesterase reaction to release AEA, or direct hydrolysis of lyso-NAPE by 
lysophospholipase D (lyso-PLD) to form AEA (Figure 4A). Interestingly, despite the fact that AEA levels 
were not changed in NAPE-PLD mice (Leung et al., 2006) both lyso-NAPE and GP-AEA levels were 
increased (Tsuboi et al., 2013). Additionally, by analyzing this KO mouse line, it was suggested that 
AEA can also be formed not only from NAPE, but also from N-acylated plasmenylethanolamine via 
both, NAPE-PLD-dependent and -independent pathways (Tsuboi et al., 2013). 
Next to the complexity of possible synthesis pathways, degradation of AEA can occur via three 
different pathways: 1) Hydrolysis by fatty acid amino hydrolase (FAAH), 2) hydrolysis by N-
acylethanolamine-hydrolysing acid amidase (NAAA) to arachidoic acid (AA) and ethanolamine or 3) 
oxidation by cyclooxygenase-2 (COX-2) to create prostamides (Figure 4B). Metabolism via FAAH is 
considered to represent the major pathway for AEA degradation.  
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However, inhibition of FAAH may be compensated by the alternative pathways, altering cell 
functions independently of the endocannabinoid system due to the engagement of for example the 
COX-2 pathways (Tsuboi et al., 2013). 
 
 
Figure 4: Metabolism pathways for AEA and 2-AG. 
 A: Synthesis and degradation (B) of AEA. C: Synthesis and degradation (D) of 2-AG. Modified from Lu 
and Mackie, 2016. 
 
1.2.2.2 2-AG  
 2-AG is the most prevalent endocannabinoid in the CNS expressing much higher concentrations than 
AEA and acts as a full agonist to CB1R and CB2R, suggesting that 2-AG is a true natural ligand for the 
cannabinoid receptors (Kano et al., 2009). Same as AEA, 2-AG is synthesized on demand in response 
to neuronal activity (Di et al., 2005). 
The major part of 2-AG is produced by hydrolysis of arachnidonyl-containing phosphatidylinositol 
4,5-biphosphate (PIP2) by PLC followed by hydrolysis of the resulting DAG by DAG lipase (DAGL) to 
release 2-AG (Figure 4C). The first step of 2-AG synthesis can be engaged by stimulation of GPCRs 
that activate PLC via Gq/11, including group I metabotropic glutamate receptors (mGluR; Maejima et 
al., 2001; Varma et al., 2001) and muscarinic acetylcholine receptors (mACh; Kim et al., 2002; Ohno-
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Shosaku et al., 2003). This activation leads to the production of DAG, the precursor of 2-AG. 
Intracellular Ca2+ elevation following depolarization or neuronal activity was shown to trigger 2-AG 
release (Kreitzer and Regehr, 2001a; Kreitzer and Regehr, 2001b; Ohno-Shosaku et al., 2001; Wilson 
and Nicoll, 2001) due to a Ca2+-dependent enzymatic activity of PLC. In fact, synergetic effects of 
both stimuli (mild GPCR activation combined with weak depolarization) have been reported to 
prominently enhance 2-AG release (Kim et al., 2002; Ohno-Shosaku et al., 2003; Ohno-Shosaku et al., 
2002a; Varma et al., 2001). Although 2-AG can be produced in a Ca2+ or PLC-independent manner, 
Ca2+-assisted PLC activation has been suggested to underlie physiological cannabinoid release 
during synaptic transmission (Kano et al., 2009) in which PLC acts as a coincidence-detector 
inducing cannabinoid production (Figure 5). In line with these findings, PLC1 was reported to form 
clusters that were found in somatodendritic locations and in close proximity to mGluR, mACh and 
DAGL (Fukaya et al., 2008). 
DAGL is a Ca2+-activated enzyme expressed in two isoforms: DAGL and DAGLGeneration and 
analysis of transgenic mice lacking either of the two enzymes showed that DAGL is exclusively 
responsible for the production and release of 2-AG at synapses in the CNS (Tanimura et al., 2010). 
Electronmicroscopical analysis of DAGL expression reported its postsynaptic location. The opposing 
excitatory presynaptic sites of the DAGL-expressing postsynaptic regions were found to be 
equipped with CB1Rs supporting the importance of DAGL in endocannabinoid production. 
Surprisingly, DAGL expression was rarely found opposed to CB1R-expressing inhibitory terminals 
contacting perisomatic sites of the cells, although these connections show strong expression of 
endocannabinoid-mediated plasticity mechanisms (see chapter 1.2.4; Katona et al., 2006; Yoshida et 
al., 2006).  
In an additional complementary pathway for 2-AG production phosphatidiylinositol (PI) is cleaved by 
phospholipase A1 (PLA1) to lyso-PI followed subsequent conversion to 2-AG by lyso-PLC (Figure 4C). 
Degradation of 2-AG primarily occurrs via three hydrolytic enzymes to form arachidonic acid and 
glycerol (Figure 4D): 85% of 2-AG hydrolysis is performed by monoacylglycerol lipase (MAGL) while 
the remaining part is mostly catalyzed by /-Hydrolase domain containing enzyme (ABHD) 6 and 
ABDH12 (Blankman et al., 2007). These three enzymes have different cellular and subcellular 
expression patterns: In contrast to presynaptic localization of MAGL (opposing postsynaptic DAGL), 
ABDH6 and 12 are mainly expressed in dendrites and dendritic spines suggesting diverging functions 
of these enzymes (Figure 5). Additionally, 2-AG can be oxidized by COX-2 or hydrolyzed by FAAH (Lu 
and Mackie, 2016), representing an overlap with degradation of AEA. Interestingly, metabolism of 2-
AG by COX-2 leads to the formation of prostaglandin 2 glycerol ester (PGE2-GE) that was shown to 
14 
 
potentiate synaptic transmission and plasticity (Sang et al., 2006). Thus, different physiological or 
pathological conditions that modulate the endocannabinoid system might not only alter 2-AG levels, 
but can also lead to altering degradation pathways that result in modifications of endocannabinoid-
independent systems. 
 
1.2.2.3 Noladin Ether 
A third putative endocannabinoid is 2-arachinodyl glycerol ether (noladin ether), which was isolated 
in 2001 from porcine brain. Noladin ether shows a selective binding to CB1Rs in the nanomolar range 
but only a weak binding to CB2Rs (Hanus et al., 2001; Table 2). In addition, noladin ether was shown 
to act independently of cannabinoid receptors as an agonist for TRPV1 channels (Duncan et al., 
2004). Noladin ether production is increased by the cholinomimetic drug carbachol causing sedation, 
hypothermia, intestinal immobility and mild antinociception in mice (Hanus et al., 2001). 
 
1.2.2.4 NADA 
NADA is an endogenous lipid found especially in the hippocampus, cerebellum and striatum. NADA 
acts as full agonists of CB1Rs (Bisogno et al., 2000) and TRPV1 channels (Huang et al., 2002). 
Interestingly, NADA was shown to act on both, CB1Rs and TRPV1 channels in dopaminergic neurons: 
While higher NADA concentrations preferentially activate CB1Rs leading to decreased inhibitory 
transmission, facilitation of glutamate release via TRPV1 channels only occurs after reuptake of 
NADA via endocannabinoid membrane transporters (Marinelli et al., 2007). The synthesis pathways 
for NADA production are not completely understood yet, however it was observed that NADA 
synthesis occurs almost exclusively in dopaminergic terminals. For degradation, NADA is hydrolyzed 
by FAAH to dopamine and AA (Huang et al., 2002). Thus, NADA acts as a competitive inhibitor for AEA 




Virodhamine (-arachidonoyl ethanolamine) is an endocannabinoid that is found in similar 
concentrations as AEA in human hippocampus and in rat brain. In contrast to the amide linkage of AA 
and ethanolamine in AEA, virodhamine contains the opposite chemical linkage: An ester. Thus, its 
name derives from the Sanskrit word virodha, which means opposition. Virodhamin acts as 
antagonist of CB1Rs and agonist of the CB2Rs (Porter et al., 2002). A recent study described the 
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connection between the endocannabinoid and the monoaminergic neurotransmission systems in 
which virodamine and related analogues inhibited activity of monoamine oxidase (MAO; Pandey et 
al., 2018). 
In summary, unlike most other GPCRs, cannabinoid receptors appear to have more than one 
endogenous agonist. Different endocannabinoids alter in their affinities to the classical cannabinoid 
receptors as well as their activation potency for other receptor targets (see chapter 1.2.1.3). Thus, 
the endocannabinoid system represents a versatile tool for the regulation of various physiological 
and pathological processes (Di Marzo and De Petrocellis, 2012). 
 
1.2.2.6 Mobilization of endocannabinoids  
Although some evidences suggested that pre-formed 2-AG stores exist, it is now considered that 
endocannabinoids are produced and released on demand in an activity-dependent manner. As 
lipophilic compounds, endocannabinoid cannot be stored in vesicles and exocytotic endocannabinoid 
release can be excluded since 2-AG release was not affected by Butolinum toxin (Ohno-Shosaku et 
al., 2001; Wilson and Nicoll, 2001). The diffusion and spread of the endocannabinoids after their 
production is further discussed in chapter 1.2.4.2. 
It appears intuitively plausible, that cannabinoids interact with the plasma membrane and diffuse 
laterally within the cell membrane to reach the effector receptors. Despite the fact that multiple 
orthosteric binding sites on CB1Rs are associated with the extracellular domain (Saleh et al., 2018), 
several agonists (including AEA) were shown to interact with intermembrane regions of CB1Rs (Song 
and Bonner, 1996a). AEA inserts readily and stably into cholesterol-containing membrane bilayers to 
form AEA/cholesterol complexes that laterally diffuse in the membrane or facilitate the transport 
across the cell membrane (Di Pasquale et al., 2009). In addition, the crystal structure of CB1Rs 
revealed the association of cholesterol with the receptor for stabilization. A model suggests that 
cholesterol molecules surrounding CB1Rs attract the AEA/cholesterol complex and thereby guide AEA 
to the agonist-binding site of the CB1R, where the high affinity of AEA to CB1Rs leads to AEA 
dissociation from cholesterol followed by binding and activation of CB1R (Di Scala et al., 2018). 
Cholesterol enrichment of cell membranes was shown to reduce the binding efficiency and the 





Figure 5: Synaptic function of the endocannabinoid system.  
Presynaptic transmitter release (black points) leads to activation of metabotropic receptors 
(mGluR1/5, mACh1/3) and depolarization at the postsynaptic site. Together both stimuli can induce 
synthesis of endocannabinoids (2-AG DAGL and AEA by NAPE-PLD). Endocannabinoids are released 
after production and can activate CB1Rs on astrocytes, the presynaptic plasma membrane or 
presynaptic mitochondria. On the presynaptic site, CB1R activation leads to inhibition of VGCC, GIRK 
channels, AC and mitochondrial PKA activity, resulting in suppression of transmitter release. 
Astrocytic CB1R activation increases intracellular Ca
2+ and induces gliotransmitter release. Adapted 
from Araque et al., 2017.  
 
1.2.3 Role of cannabinoid system in behavior and diseases  
Plant extracts of Cannabis Sativa have been used for a long time since their medical benefits were 
known for different applications related to inflammation, pain, anxiety and food-intake. 
Administration of cannabis or pure THC to animals led to the identification of a classical behavioral 
patterns tetrad including hypoactivity, hypothermia, antinociception and catalepsy (Martin et al., 
1991). Most of these effects were not observed when CB1Rs were pharmacologically blocked or 
genetically disrupted (Ledent et al., 1999; Zimmer et al., 1999). However, deletion of CB1Rs did not 
alter THC-induced analgesic and immunosuppressive effects as well as several physiological 
behaviors (Zimmer et al., 1999). In contrast, deletion of CB2Rs abolished THC effects on immune cells 
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while the observed cannabinoid effects on the central nervous system were unaltered (Buckley et al., 
2000). Although it is still under debate, a broad line of research, including behavioral and 
electrophysiological experiments, showed evidence for the existence of functional CB2Rs in neuronal, 
glial and endothelial cells (reviewed in Jordan and Xi, 2019). 
 
1.2.3.1 Anxiety and depression 
Even if there are no direct experimental data on the role of endocannabinoids on anxiety in humans, 
numerous publications demonstrated this link in animal models. Analysis of CB1R or DAGL deficient 
mice revealed enhanced anxiety, stress and fear responses and depression-like behavior (Jenniches 
et al., 2016; Martin et al., 2002). Pharmacological inhibition of the endocannabinoid degrading 
enzymes FAAH and MAGL enhanced brain cannabinoid levels and produced anxiolytic effects in rats, 
whereas the CB1R inverse agonist rimonabant induced anxiogenic behavior (Mechoulam and Parker, 
2013). Rimonabant was developed by Sanofi (Paris, France) and was marketed under the trade name 
Acomplia in 2006 as a treatment against obesity. However, patients treated with rimonabant had 
enhanced depression- and anxiety-related symptoms (Christensen et al., 2007), leading to its 
worldwide withdrawal in 2008. Interestingly, effects of anxiolytic drugs like bromazepam and 
buspirone, which are thought to act in a cannabinoid receptor-independent manner, were abolished 
in CB1R KO mice (Uriguen et al., 2004). In line with this finding, it was shown that cannabinoids and 
CB1Rs activation can modulate the noradrenergic and serotonergic system. This interaction may 
represent the mechanism by which cannabinoid-related substances induce their anxiolytic and 
antidepressant effects (Mendiguren et al., 2018). 
Unlike for the CB1R, the role of CB2Rs in anxiety is controversial: On the one hand, genetic 
manipulation or pharmacological intervention of the CB2R showed that CB2R activation reduces 
anxiety- and depression-like behavior (Busquets-Garcia et al., 2011; Garcia-Gutierrez and 
Manzanares, 2010; Ortega-Alvaro et al., 2011). In contrast, chronic activation of CB2Rs was shown to 
increase anxiety, while blockade of CB2Rs had anxiolytic effects (Garcia-Gutierrez et al., 2012). 
Further, injection of CB2R antisense oligonucleotide into mouse brain induced anxiolytic behavior in 
mice. Analysis of the incidence of a polymorphism of the CB2 gene in humans demonstrated an 
increased prevalence of one isoform in Japanese patients suffering from depression or alcoholism 
(Ishiguro et al., 2007; Onaivi, 2006; Onaivi et al., 2008). Analysis of CB2R protein and gene expression 
in suicide victims revealed that relative gene expression of CB2R-A isoform was significantly lower 
while overall CB2R protein expression was higher compared to the corresponding control group 
(Garcia-Gutierrez et al., 2018). In line with this, CB2R expression was down regulated in mice that 
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experienced emotional or immunological stress, increasing the risk of depression-like behaviors that 
may be linked with neuro-immune crosstalk (Ishiguro et al., 2007; Ishiguro et al., 2018). Specific 
deletion of CB2Rs on dopaminergic neurons modulates animal behavior in anxiety- and depression-
like paradigms (Liu et al., 2017). In addition, the behavioral tetrad induced by cannabinoids, which 
was classically associated with CB1R activation, was altered in these animals. It was also shown that 
hippocampal CB2R expression can be rapidly upregulated during anxiogenic social interaction and 
fear conditioning (Robertson et al., 2017).  
Despite some contradictions, these studies convincingly showed that CB2Rs are involved in anxiety-
like behaviours. While CB1Rs activation has clearly anxiolytic effects, CB2Rs seem to modulate 
anxiety-related behavior in a more complex pattern. 
 
1.2.3.2 Learning and memory 
Research on the effects of marijuana has shown that cannabis intake can lead to memory loss in 
humans and animals. A systematic review analyzed 105 publications on the acute and chronic effects 
of cannabinoids in humans and summarized that verbal learning and memory as well as attention is 
consistently impaired by acute and chronic exposure to cannabis (Broyd et al., 2016). Multiple animal 
models and a wide range of behavioral paradigms have been used to assess the effects of 
cannabinoids on various stages of memory formation (acquisition, consolidation, retrieval and 
extinction). The major effects of cannabinoid application include impairment of working memory and 
long-term memory formation (Kruk-Slomka et al., 2017). Although the exact cellular mechanisms by 
which cannabinoids modulate memory-related processes are unknown, several studies showed that 
these effects are mediated by CB1Rs expressed on hippocampal GABAergic interneurons 
(Puighermanal et al., 2009), astrocytes (Han et al., 2012) or by mitochondrial CB1Rs (Hebert-Chatelain 
et al., 2016). A recent study demonstrated that endocannabinoids control synaptic plasticity and 
memory in a cell-autonomous manner by which postsynaptic CB1Rs modulate the activity of 
hyperpolarization-activated cyclic nucleotide-gated channels regulating dendritic excitability (Maroso 
et al., 2016). 
Deletion of CB2Rs in mice impairs long-term fear memory (Garcia-Gutierrez et al., 2013), and 
manipulation of CB2R expression in CA1 PC or microglia was shown to induce distinct 
behavioral phenotypes in mice: While microglial CB2Rs were involved in contextual fear memory, 
overexpression or disruption of CB2Rs in PC lowered anxiety levels or enhanced spatial working 
memory, respectively (Li and Kim, 2017). In conclusion, although the effects of cannabis 
administration on learning and memory are well studied in animal models, it is still unclear how the 
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physiological effects of the endocannabinoid system affect learning and memory. In fact, it was 
suggested that local repetitive activation of the endcannabinoid system is beneficial for working 
memory (Carter and Wang, 2007) and low dose of THC reversed an age-related decline in cognitive 
performance (Bilkei-Gorzo et al., 2017). Activation of CB2Rs was also shown to restore cognitive 
function in a mouse model of Alzheimer’s disease (Wu et al., 2017). 
 
1.2.3.3 Neuroprotective effects of endocannabinoids 
In various pathological states including neuroinflammation and neurodegenerative disorders 
different components of the endocannabinoid systems (endocannabinoids, CB1R and CB2R) were 
shown to be upregulated (Pertwee, 2015). Combined with the demonstrated neuroprotective effects 
of the endocannabinoid system (Fernandez-Ruiz et al., 2010) this may reflect the system’s response 
to the pathological brain states. The endocannabinoid system is involved in different beneficial 
mechanisms during pathological brain states: It plays a key role in the death/survival cell decision, 
attenuates generation of reactive oxygen species and induces vasodilation to improve blood supply 
to injured brain areas (Fernandez-Ruiz et al., 2010). It was hypothesized that enhanced glutamatergic 
signaling and chronic excitotoxicity, which occurs in numerous neurodegenerative diseases 
(Lewerenz and Maher, 2015) leads to an increased production of endocannabinoids and elevated 
presynaptic CB1R activation. In addition, activation of the endocannabinoid system was shown to 
decrease epileptic activity: 2-AG can supress seizures and epileptogenesis by reducing excitatory 
synaptic inputs in the dentate gyrus through CB1R and CB2Rs (Sugaya et al., 2016).  
Especially, but not exclusively, activation of microglial CB2Rs was demonstrated to induce potent 
anti-inflammatory effects. In contrast to low CB2R expression under physiological conditions, 
microglial CB2R is expression dramatically increased in a variety of pathological conditions including 
neuroinflammation (Caslisle et al., 2002; Zoppi et al., 2014), stroke (Yu et al., 2015; Zarruk et al., 
2012), Parkinson’s disease (Concannon et al., 2015, 2016), Alzheimer’s disease (Benito et al., 2003) 
and Huntington’s disease (Palazuelos et al., 2009). Also, neuronal CB2R expression is increased in 
neuropathic pain (Svizenska et al., 2013), drug addiction (Zhang et al., 2014, 2017) and CB2R protein 
expression was increased in suicide victims (Garcia-Gutierrez et al., 2018). According to these data 
Pacher and Mechoulam suggested that CB2R signaling might represent a protective system that 




1.2.3.4 Therapeutic use of cannabinoids 
Considering the involvement of the endocannabinoid system in a variety of pathological conditions, a 
plethora of clinical trails have been performed to determine the therapeutic potential of 
cannabinoids (search for cannabinoids: 375 registered trails on ClinicalTrails.gov; 696 clinical studies 
and case reports on database by International Association for Cannabinoid Medicines; acced on 
March 22 2019). 
Some cannabinoid-based medications have already been approved for the treatment for various 
pathological conditions: A synthetic analog of THC (Nabilone) and an isoform of THC (Dronabinol) are 
used for treatment of nausea and vomiting induced by chemotherapy (Fraguas-Sánchez and Torres-
Suárez, 2018). Plant extracts from Cannabis Sativa (Nabiximols; trade name: Sativex), mainly 
containing THC and cannabidiol (at a ratio 1:1) are used for the treatment for spacticity and pain 
associated with multiple sclerosis and for palliative treatments in patients with advanced cancer. 
Pure plant-derived cannabidiol (trade name: Epidiolex) has recently been approved for treatment of 
two severe and refractory forms of pediatric-onset epilepsies: Lennox-Gaustat syndrome and Dravet-
syndrome (Billakota et al., 2019; Sekar and Pack, 2019). Several studies have shown that cannabidiol 
interacts with various cannabinoid-related and non-related targets: It acts as an antagonist for CB1Rs 
and GPR55 as well as inverse agonist of CB2R (Ryberg et al., 2007; Thomas et al., 2007) and inhibits 
AEA uptake and degradation resulting in increased endocannabinoid levels (Billakota et al., 2019; 
Campos et al., 2012). Further, cannabidiol is an agonist of TRPV1, TRPV2, 5-HT1A and 5-HT2A receptors 
and an antagonist for 5-HT3 and TRPM8 receptors. It acts as an allosteric modulator of opioid 
receptors and blocks reuptake of adenosins (Campos et al., 2012). However, the exact mechanisms 
by which cannabidiol-induced therapeutic effects are mediated have not been determined. 
 
1.2.3.5 Endocannabinoid system as target for drug-discovery research 
Despite the involvement of the endocannabinoid system in a variety of pathological states, only a 
few compounds targeting the endocannabinoid system have reached the therapeutic market 
(chapter 1.2.3.4). Due to the ubiquitous expression of CB1Rs in the CNS and its involvement in 
multiple physiological processes, pharmacological manipulation of CB1Rs leads to several side effects 
including psychotropic actions (Fraguas-Sánchez and Torres-Suárez, 2018).  
Hence, CB2Rs are considered to represent a more promising target for treatment of CNS-related 
diseases due to their low expression levels in physiological conditions that is upregulated in a variety 
of pathological states (Dhopeshwarkar and Mackie, 2014). This pathology-induced expression of 
CB2Rs implicates a disease-associated target for pharmacotherapeutic treatment without strong side 
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effects in healthy states. Further, CB2R activation showed to mediate potent anti-inflammatory 
effects that can be beneficial in most neurological diseases (Basavarajappa et al., 2017). Since specific 
CB2R activation does not have psychoactive side effects associated with CB1R activation (Pertwee, 
2012), CB2Rs represent an excellent potential target for drug-discovery research. 
 
1.2.4 Physiological effects of cannabinoids on synaptic transmission 
After the discovery of the endocannabinoid system in the early 1990s, a plethora of the well-known 
effects of marijuana could be investigated in more detail and were mainly mimicked by CB1R 
activation. Numerous studies were performed to identify and locate the key elements of the 
endocannabinoid system. In addition, the development of transgenic animals lacking the cannabinoid 
receptors (Buckley et al., 2000; Ledent et al., 1999; Zimmer et al., 1999) shed further light into the 
role und function of one of the major physiologically important systems. The initial studies of CB1R 
KO mice described that transgenic animals did not respond to cannabinoid drugs as opposed to their 
wild type (WT) littermates indicating the role of CB1R in analgesia, reinforcement, hypothermia, 
hypolocomotion, and hypotension (Ledent et al., 1999; Zimmer et al., 1999). In addition several 
phenotypes of the CB1R deficient mice were described, including increased mortality, hypoalgesia, 
hypoactivity (Zimmer et al., 1999) and CB1Rs were considered to be responsible for all cannabinoid 
related effects in the CNS. Further, several studies have elucidated the effects of cannabinoids on 
developing organisms, especially in regard to the CNS as well as characterized the presence of 
components of the endocannabinoid system during development (Fernandez-Ruiz et al., 2000).  
During the 1990s, the discovery of the endocannabinoid system and the systematic study of 
transgenic KO animals of its key component established a detail understanding of the functional 
anatomy and the molecular mechanisms for cannabinoid signaling. However, the physiological role 
of the endocannabinoid system remained elusive, since the physiological stimuli for 
endocannabinoid production and release were not understood yet.  
In the meantime a phenomenon was identified in which an unknown retrograde messenger was 
released upon depolarization of a postsynaptic neuron to suppress inhibitory input (DSI: 
Depolarization-induced suppression of inhibition, Figure 6; Pitler and Alger, 1992). Four publications 
from different laboratories were published in three different journals on the 29th March 2001 and 
unequivocally demonstrated that cannabinoids represent the long-sought retrograde messengers. 
One publication proposed a model suggesting that endocannabinoids represent retrograde 
messengers (Elphick and Egertova, 2001), and experimental data from hippocampal (Wilson and 
Nicoll, 2001) and cerebellar brain slices (Kreitzer and Regehr, 2001a), as well as from cultured 
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hippocampal neurons (Ohno-Shosaku et al., 2001) supported the hypothesis that endocannabinoids 
are produced and release postsynaptically to inhibit neurotransmitter release from presynaptic 
terminals.  
 
1.2.4.1 Short-term plasticity 
Endocannabinoids were shown to act as retrograde messengers: Activation of the postsynaptic cell, 
by Ca2+ increase or due to activation of Gq/11 GPCRs lead to activation of endocannabinoid 
synthesizing enzymes and the release of endocannabinoids. The endocannabinoids bind to 
presynaptic CB1Rs (Figure 5) and transiently inhibit transmitter release for tens of seconds. In acute 
hippocampal brain slices and in cultured hippocampal neurons DSI in PC was mimicked and occluded 
by activation of CB1Rs and DSI was abolished with CB1R antagonists (Ohno-Shosaku et al., 2001; 
Wilson and Nicoll, 2001). At cerebellar excitatory synapses a similar phenomenon was identified in 
which endocannabinoids inhibit glutamate release upon binding to presynaptic CB1Rs and it was 
called depolarization-induced suppression of excitation (DSE; Kreitzer and Regehr, 2001a, b). This 
inhibition of glutamate release was accompanied with presynaptic Ca2+ decrease and was blocked by 
application of Ca2+ chelators into the postsynaptic cell. 
2-AG is considered to represent the major endocannabinoid responsible for modulation of synaptic 
transmission since both DSI and DSE were absent in DAGL deficient animals (Tanimura et al., 2010). 
Strong activation (one brief depolarization step or several APs) of the postsynaptic cell leads to an 
increase in intracellular Ca2+ via voltage-gated Ca2+ channels (VGCC; Pitler and Alger, 1992) or NMDA 
receptors (Ohno-Shosaku et al., 2007), which induces PLC and DAGL to produce 2-AG. In addition, 
a Ca2+-independent mechanism was described in which activation of GPCRs (including mGluR, mACh 
and cholecystokinin-receptors) activate PLC via the Gq/11 subunit to produce DAG that is 
subsequently metabolized to 2-AG (metabotropic suppression of inhibition/excitation; MSI/MSE; Lu 
and Mackie, 2016). Despite the Ca2+-independency of MSI/MSE, the Ca2+ sensitivity of PLC results in 
synergetic action of metabotropic and depolarization-induced 2-AG production and suppression of 
transmitter release. Thus, these two forms of endocannabinoid production can serve as coincidence-
detector of Gq/11 signaling, postsynaptic depolarization and Ca
2+ influx. Importantly, it was reported 
that stimulation of presynaptic neurons can induce postsynaptic 2-AG production via mGluR1 and 




After production and release, 2-AG binds to presynaptic CB1Rs on inhibitory (for DSI and MSI) or 
excitatory (for DSE and MSE) axon terminals resulting in reduction in transmitter release via 
inhibition of VGCC (mainly N-type, under some conditions also L-type Ca2+ channels; Foldy et al., 
2006; Lenz et al., 1998). In addition, mitochondrial CB1Rs were shown to contribute to DSI in 
hippocampal PCs by regulating neuronal respiration and energy production (Benard et al., 2012). 
Short term modulation of synaptic transmission by endocannabinoids was described for numerous 
synapses in multiple brain regions including hippocampal CA1 and CA3 PC, dentate granule cells, hilar 
mossy cells and hippocampal cholecystokinin-positive interneurons, cerebellar Purkinje cells, basket 
cells and stellate cells, striatal medium spiny neurons, neurons in the globus palidus and in substantia 
nigra pars reticulare and pars compacta, in layers 2/3 and 5 PC of the somatosensory cortex, in the 
amygdala, the hypothalamus as well as in the brainstem (reviewed by Kano et al., 2009). 
 
 
Figure 6: High-frequency trains of APs transiently reduce inhibitory potentials in hippocampal PCs. 
Spontaneous inhibitory potentials were recorded in CA1 PCs with KCl-filled electrodes (positive 
voltage deflection; Pitler and Alger, 1992). Voltage-clamp recordings were performed in the presence 
of ionotropic glutamate receptor antagonist and carbachol to isolate and increase inhibitory 
transmission, respectively. Example trace shows that a brief AP train (black bar) induced a transient 
suppression of inhibitory events (depolarization-induced suppression of inhibition: DSI). Modified 
from Pitler and Alger, 1992. 
 
1.2.4.2 Spread of endocannabinoids 
The hydrophobic nature of endocannabinoids allows the lateral diffusion in the cell membrane to 
activate adjacent cannabinoid receptors but it raised the question of how these lipid molecules can 
diffuse through the synaptic cleft to act on the presynaptic site. It was also unknown whether these 
diffusible messengers can spread to modulate nearby synapses. It was reported for neighboring 
hippocampal PCs that depolarization of one neuron caused a suppression of inhibition in the 
adjucent neurons when they were separated by 20 µm or less (Ohno-Shosaku et al., 2000; Wilson 
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and Nicoll, 2001). In the cerebellum it was demonstrated that MSE does not spread to neighboring 
cells (Maejima et al., 2001), while DSI can spread from one Purkinje cell to another at a distance of 70 
µm (Vincent and Marty, 1993). Further studies reported that depolarization of a Purkinje cell can 
inhibit neighboring excitatory and inhibitory cells at room temperature but only inhibitory cells at 
physiological temperature (Kreitzer et al., 2002). However this inhibition is not mediated by the 
direct long-range spread of the endocannabinoids but rather occurs due to activation of somatic K+ 
channels at the interneurons, which can project over several hundred micrometers (Kreitzer et al., 
2002). Thus, the biophysical mechanism by which the hydrophobic endocannabinoids can spread 
even short distances remains unclear.  
 
1.2.4.3 Termination of endocannabinoid signaling  
The short time course of DSI/DSE and MSI/MSE is caused by the rapid termination of the 
endocannabinoid signal due to enzymatic degradation. It is thought that both neurons and glial cells 
express transporters and degradation enzymes for endocannabinoids, and that they collaborate in 
endocannabinoid clearance of the extracellular space (Pertwee, 2015). While a lot of research was 
performed on AEA reuptake, relatively little is known about 2-AG. However, uptake parameters of 
both endocannabinoids share similar properties including temperature dependency, saturability and 
sensitivity to endocannabinoid reuptake blockers (including AM404 and OMDM-2). Additionally, AEA 
uptake is also inhibited by 2-AG, AA and noladin ether suggesting the presence of a general 
endocannabinoid plasma membrane transporter. Although putative endocannabinoid transporters 
have not been identified yet, specific endocannabinoid reuptake blockers are widely used in research 
to enhance extracellular endocannabinoid levels. Interestingly, these uptake blockers were reported 
to inhibit endocannabinoid release suggesting a bidirectional endocannabinoid transport across the 
plasma membrane (Seillier and Giuffrida, 2018). 
It is still under debate if membrane bound transporters exist or if alternative models could explain 
the experimental observation. One alternative model for endocannabinoid transport utilizes the lipid 
structure of AEA and 2-AG and hypothesizes their association with the cell membrane and passive 
diffusion into the cell without the need for a specific membrane transporter. Passive diffusion would 
only be possible until extra- and intracellular level would reach equilibrium. However, activity of 
intracellular degrading enzymes (FAAH, MAGL) creates an endocannabinoid gradient that enables 
further translocation of endocannabinoids into the cell. For AEA it is adequately described that it 
diffuses across the cell membrane and is subsequently transported by intracellular carriers to the 
effector molecules (such as intracellular CB1Rs or TRPV1 channels) or catabolic enzymes (Di Scala et 
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al., 2018; Fowler, 2013). These carriers are inhibited by endocannabinoid membrane transporter 
inhibitors. In addition, endocytosis was proposed to represent an important route for AEA uptake 
(McFarland et al., 2008). Different entry routes might even co-exist, meaning that the uptake of AEA 
might depend on the cell type as well as the physiological state of the cells, and a lot more research 
is needed to shed further light on this process and especially on the uptake of 2-AG. 
 
1.2.4.4 Long-term plasticity 
Next to the short-term modulation of synapses endocannabinoids are also involved in the induction 
of long-term changes of synaptic strength. High frequency stimulation of excitatory cortico-striatal 
synapses paired with postsynaptic depolarization induced long-lasting depression of presynaptic 
transmitter release due to postsynaptic AEA production (Gerdeman et al., 2002). In nucleus 
accumbens, presynaptic stimulation induced postsynaptic activation of mGluR5 receptors triggering 
endocannabinoid release that induced long-lasting presynaptic decrease in transmitter release 
(Robbe et al., 2002). Pairing of presynaptic stimulation with postsynaptic depolarization also induces 
long term depression (LTD) in cortical layer 5 PCs in which coincident activation of presynaptic NMDA 
receptors and CB1Rs causes long-lasting synaptic depression (Sjöström et al., 2003). In addition, a 
heterosynaptic form of LTD was described in CA1 PC in which presynaptic stimulation of excitatory 
synapses leads to mGluR-mediated endocannabinoid release that induces LTD on nearby GABAergic 
terminals (Chaveleyre and Castillo, 2003). 
In contrast to the inhibition of N-type VGCC by G for endocannabinoid induced short-term 
plasticity, the predominant mechanism for endocannabinoid induced long-term LTD requires 
reduction of the cAMP/PKA pathways by Gi/o following CB1R activation (Chevaleyre et al., 2007). 
Moreover, CB1R activation alone (pharmacologically or via repeated DSI induction) is not sufficient to 
induce LTD. Simultaneous presynaptic neuronal activity is crucial for LTD induction and CB1R 
activation is only important during the induction phase but not in the expression phase (Castillo et 
al., 2012). 
Besides the presynaptic forms of LTD, an endocannabinoid-dependent form of postsynaptic LTD was 
also described (Grueter et al., 2010). Presynaptic glutamate release triggers postsynaptic AEA 
production via mGluR5. In addition to acting on presynaptic CB1Rs to induce LTD, AEA activates 
TRPV1 channels resulting in AMPA receptor endocytosis (Grueter et al., 2010). 
In contrast to the general inhibitory action of endocannabinoids, several recent studies indicated that 
endocannabinoids can also participate in the induction of unconventional forms of long-term 
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potentiation (LTP). High frequency stimulation of the lateral perforated path triggers a presynaptic 
form of LTP, which is induced by CB1R activation. Presynaptic neuronal activity results in transmitter 
release that leads to postsynaptic activation of mGluR5 and NMDA receptors. This induces 
endocannabinoid production and release to stimulate presynaptic CB1Rs (Wang et al., 2016). In 
addition, layer 5 PC were shown to express a brain-derived neurotrophic factor-dependent form of 
LTP, where AP firing triggers endocannabinoid production and results in decreased inhibition onto 
the cell enabling increased Ca2+ influx and brain-derived neurotrophic factor production to induce 
LTP on excitatory synapses (Maglio et al., 2018). Paired pre- and postsynaptic stimulation of cortical 
or striatal principal cells resulted in an endocannabinoid dependent form of LTP that is NMDA 
receptor-independent but requires the simultaneous activation of CB1Rs and TRPV1 receptors (Cui et 
al., 2016, 2018). 
 
1.2.4.5 Involvement of glial cells in cannabinoid mediated synaptic modulation  
Cannabinoid receptors as well as their synthesizing and degrading enzymes are also present in glial 
cells including astrocytes, oligodendrocytes and microglia. CB1R and CB2R expression in microglia 
changes depending on their phenotype and activation profile: While only low expression levels can 
be detected in healthy brains, especially CB2R expression is highly increased under pathological 
conditions (see chapter 1.2.3).  
Several studies confirmed the expression of CB1R in astrocytes (Araque et al., 1999, 2017; Navarette 
and Araque, 2010; Gomez-Gonzalo et al., 2015). These cells extend their processes to the synaptic 
cleft and can influence synaptic transmission, creating a functional entity with the pre- and 
postsynaptic site that has been named tripartite synapse (Araque et al., 1999). Activation of CB1Rs on 
hippocampal astrocytes leads to increased intracellular Ca2+ that is mediated via activation of Gq/11 
proteins and leads to PLC stimulation and release of Ca2+ from intracellular stores (Araque et al., 
2017). Increase of the intracellular Ca2+ can trigger release of gliotransmitter that were shown to 
activate pre- or postsynaptic sites of the neighboring synapses (Figure 5). Stimulation of presynaptic 
excitatory cells with paired depolarization of postsynaptic layer 2/3 PC in somatosensory cortex leads 
to endocannabinoid release from the postsynaptic cell. These endocannabinoids can activate 
astrocytic CB1Rs resulting in astrocytic glutamate release and presynaptic NMDA receptor activation 
to induce LTD (Min and Nevian, 2012). Additionally, while endocannabinoids acting on homosynaptic 
neuronal CB1Rs induce DSE, they can also induce heterosynaptic short-term facilitation through 
activation of astrocytic CB1Rs (Navarrete and Araque, 2010). Thus, astrocytes might also be involved 
in heterosynaptic regulation of synaptic strength since they span over several hundred micrometers 
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and form contacts to numerous dendrites and synapses. Interestingly, an in vivo study using cell 
type-specific CB1R KO mice showed that impairment of working memory by marijuana and other 
cannabinoids exclusively relies on activation of astrocytic CB1Rs and is associated with astroglial-
dependent hippocampal LTP (Han et al., 2012). Goméz-Gonzalo et al. described another form of 
astrocytes-mediated long-term plasticity in 2015: Endocannabinoids were shown to induce LTP at a 
single hippocampal synapse through astrocyte activation when coincided with postsynaptic activity. 
Endocannabinoid-mediated activation of astrocytic CB1Rs resulting in glutamate release that binds to 
presynaptic mGluR5 receptors. Simultaneous postsynaptic nitric oxide production and presynaptic 
activation of PKC results in potentiation of the excitatory synapse (Gomez-Gonzalo et al., 2015). In 
addition to glutamate, multiple different gliotransmitters contributing in synaptic plasticity were 
described to be released from astrocytes upon ligand binding to CB1Rs. For example, activation of 
astrocytic CB1Rs enabled induction of LTP via exocytosis of ATP from astrocytes (Rasooli-Nejad et al., 
2014).  
It is still unclear to which extend glial cells contribute to the production of endocannabinoids for its 
synaptic action. Astrocytes as well as oligodendrocytes were shown to be able to synthesize 
endocannabinoids through Ca2+- and ATP-dependent pathways (Oliveira da Cruz et al., 2016). 
Further, a recent study showed that neurons and astrocytes coordinately regulate 2-AG content via 
MAGL-mediated 2-AG metabolism and transcellular shuttling of AA (Viader et al., 2015). 
In conclusion, glial cells, especially astrocytes, might represent an important cellular component of 
the endocannabinoid system, since they bridge pre- and postsynaptic sites and contribute to 
heterosynaptic regulation of synaptic strength. In addition, glia cells are involved in the production 
and degradation of endocannabinoids regulating its temporal and local activity. Together, the 
involvement of astrocytes in cannabinoid signaling adds an additional level of complexity to the 
endocannabinoid system. 
 
1.2.5 Cell-autonomous action of endocannabinoids 
Beside the modulation of synaptic transmission, endocannabinoids were reported to influence cell 
excitability in an autocrine or cell-autonomous manner. Postsynaptic CB1Rs were shown to regulate 
dendritic excitability by modulating the key dendritic current Ih due to activation of 
hyperpolarization-activated cyclic nucleotide-gated channels. CB1R activation leads to enhancement 
of Ih via a c-Jun-N-terminal kinases, nitric oxide synthase, and intracellular cyclic Guanosine 
monophosphate (cGMP) dependent pathway resulting in an impairment of dendritic integration of 
excitatory inputs, LTP and spatial memory formation (Maroso et al., 2016). Intracellular CB2Rs in PCs 
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of the medial prefrontal cortex were reported to open Ca2+-activated Cl- channels in an IP3R-
dependent manner (den Boon et al., 2012). AP-firing triggers 2-AG synthesis that activates 
intracellular CB2Rs resulting in reduction of neuronal excitability as a putative mechanism to prevent 
excessive neuronal firing (den Boon et al., 2014). Moreover, 2-AG was reported to increase 
spontaneous firing of isolated dopaminergic neurons by reducing A-type K+ currents in a cannabinoid 
receptor-independent manner (Gantz and Bean, 2017).  
 
 
Figure 7: Hippocampal SSI is mediated by neuronal CB2Rs and does not change the input resistance.  
A: Trains of APs induce SSI in CA3 PCs recorded in perforated patch configuration (Stempel et al., 
2016). Raw traces (upper part) show that trains of APs (white bars) elicit a long-lasting 
hyperpolarization. Lower part shows the time course of the average hyperpolarization induced by AP 
trains, as well as individual values of hyperpolarization. B: SSI is still present in CB1R KO mice (top), 
but abolished in constitutive (middle) and synapsin promoter-driven (bottom) CB2R KO mice. Left: 
Example of membrane potential in response to AP trains (white bars). Right: Average 
hyperpolarization induced by AP trains. C: Hyperpolarizing test-pulses (40 pA; in current-clamp 
configuration) were used to monitor input resistance of recorded cells. Agonist applications result in 
long-lasting hyperpolarization (membrane potential written under test pulses) but do not affect input 




Low-threshold spiking interneurons (LTS) in layer 5 of the somatosensory cortex express a form of 
self-inhibition that is mediated by CB1Rs and was named slow self-inhibition (SSI; Bacci et al., 2004). 
Trains of action potential induce the synthesis of 2-AG and lead to activation of GIRK channels (Bacci 
et al., 2004; Marinelli et al., 2008). This effect was blocked by preincubation with the CB1R antagonist 
AM-251 as well as by disrupting the intracellular Ca2+ increase via the Ca2+ chelator BAPTA or by 
blocking VGCC with Cd2+ (Bacci et al., 2004). Next to LTS interneurons, a subset of PC (approx. 30%) in 
layer 2/3 of the somatosensory cortex was shown to express SSI (Marinelli et al., 2009). A similar 
phenomenon was described in hippocampal principal cells, where trains of APs induced a long-lasting 
hyperpolarization in CA3 PCs (Figure 7A; Stempel et al., 2016). Surprisingly, pharmacological and 
genetic approaches demonstrated that hippocampal SSI is mediated by neuronal CB2Rs (Figure 7B, C; 
Stempel et al., 2016). A further difference in hippocampal and cortical SSI represents the mechanism 
for the hyperpolarization: While in cortical neurons SSI is mediated via activation of GIRK channel 
resulting in reduced input resistance (Bacci et al., 2004; Marinelli et al., 2009), hippocampal SSI is not 
accompanied with a change in input resistance (Figure 7C; Stempel et al., 2016). 
 
1.3 Aim of this study 
In my thesis I investigated the presence, function and cellular mechanisms of SSI in different 
hippocampal and cortical cell types. SSI is an endocannabinoid-mediated cell-autonomous effect that 
modulates neuronal excitability. When we started this project, it was not known exactly which cell 
types are capable of inducing SSI and by which mechanism it is implemented. Based on the literature 
it was unclear whether cortical SSI depends exclusively on CB1Rs or whether CB2Rs may contribute to 
its induction. The overall aim of the study was to address the question whether cortical and 
hippocampal SSI differ in their induction and establishment mechanisms, or if their occurrence and 
underlying mechanisms rely on generalized biological principles. 
First, we analyzed the cellular mechanism underlying SSI in hippocampal pyramidal neurons. Based 
on the finding that the input resistance did not change during SSI, we demonstrated that activity 
modulation of ion pumps represents the underlying mechanism (chapter3.1). Second, we 
investigated whether SSI is only present in hippocampal principle cells or if interneurons also are able 
to induce SSI (chapter 3.1.1). Third, we studied SSI in different types of cortical neurons and intended 
to characterize the involvement of different cannabinoid receptors in SSI induction as well as the 




2. Materials and methods 
2.1 Materials 
2.1.1 Technical Equipment 
Vibratome      VT 1200S (Leica, Germany) 
Interface storage chamber Haas-type (Haas et al., 1979), custom-made (Charité 
Berlin, Germany) 
Water baths      WBT series (Carl Roth, Germany) 
Peristaltic pump    Puls 3 (Gilson, USA) 
Recording chamber     submerged (Luigs and Neumann, Germany) 
Heatable perfusion cannula   with temperature sensor PH01 and temperature 
controller TC02 (Multichannel Systems, Germany) 
Oscilloscope     HM1507-3 (Hameg Instruments, Germany) 
Amplifier      Axoclamp 700B (Molecular Devices, Canada) 
Digitizer     BNC 2090 (National Instruments, USA) 
A/D Board      PCI 6035E (National Instruments, USA) 
Micromanipulators     Mini 25, 3 axes (Luigs and Neuman, Germany) 
Stimulus generator     Master 8 (A.M.P.I, Israel) 
Extracellular stimulation unit    Iso Flex (A.M.P.I, Israel) 
Glass electrode puller     DMZ Universal Puller (Zeitz Instrumente, Germany) 
Borosilicate glass capillaries    GC150TF-10 (Harvard Apparatus, UK) 
Recording and bath electrodes  AG-8W silver wire, chlorided (Science products, 
Germany) 
Upright microscope  BX-51 WI with differential interference contrast (DIC) 
optics and video microscopy (Olympus, Japan) 
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Water immersion objective    LumPlan FL/IR 60x 0.9NA (Olympus, Japan) 
Phase objective     UPlanFL N 4X×0.13 PhP (Olympus, Japan) 
Confocal microscope    DMI 6000; SP5 (Leica, Germany) 
Plastic syringes      (B. Braun, Germany)  
Perfusion tubing     (Carl Roth, Germany) 
 
2.1.2 Software 
IGOR Pro 6.12 (WaveMetrics Inc., USA) with custom-written plug-ins 
NeuroMatic (http://www.neuromatic.thinkrandom.com) 
Prism 5 (GraphPad Software, USA) 
Illustrator (Adobe Systems Inc., USA) 
Office 2007 (Microsoft, USA) 
Image J (Research Services Branch, National Institue of Health, USA)  
FIJI (Schindelin et al., 2012) 
neuTube (Feng et al., 2015) 
 
2.2 Experimental preparations 
2.2.1 Ethical Statement and Animal Handling 
Animal husbandry and experimental procedures were performed in accordance with the guidelines 
of local authorities (Berlin, Germany), the German Animal Welfare Act, and the European Council 
Directive 86/609/EEC. Animals were housed on a 12:12h reversed day-night cycle with food and 




2.2.2 Transgenic animals 
All knockout animals used in this study were kindly provided by Prof. Andreas Zimmer (Department 
of Molecular Psychiatry, University of Bonn, Bonn, Germany). CB1R- and CB2R-deficient mice (Buckley 
et al., 2000; Zimmer et al., 1999) were maintained on a C57BL/6n genetic background, and 
homozygous KO mice and their WT littermates were obtained from heterozygous breedings.  
In addition, a somatostatin reporter mouse line was used in which a somatostatin/Cre-expressing 
mouse line (Taniguchi et al., 2011) was crossed with a floxed-Ai9 mouse line (Madisen et al., 2010) 
resulting in tdTomato expression in somatostatin-expressing interneurons. 
Animal breeding and genotyping was performed by technical assistances of the laboratory. 
 
2.2.3 Preparation of brain slices 
Coronal or horizontal slices were prepared from the somatosensory cortex and the hippocampus, 
respectively, mice aged postnatal day 21-35. Animals were anesthetized with isoflurane and 
decapitated. Brains were removed and transferred to ice-cold sucrose-based artificial cerebrospinal 
fluid (sACSF; containing in mM: 87 NaCl, 26 NaHCO3, 50 sucrose, 10 glucose, 2.5 KCl, 1.25 NaH2PO4, 3 
MgCl2, and 0.5 CaCl2). Tissue blocks were mounted on a vibratome (Leica VT 1200S, Leica 
Microsystems), cut at 300 μm thickness, and stored in an interface chamber (Haas et al., 1979; Figure 
8) at 33 °C. 
Interface storage of acute slices was chosen for this study, as previous work from our laboratory 
demonstrated advantages over submerged storage in terms of excitability and network preservation 
(Maier et al., 2009). In addition, structural analysis by electron microscopy revealed an improved 
maintenance of perisynaptic astroglial processes in interface storage, which are lost or retracted 
when slices are maintained under submersion conditions (Bourne and Harris, 2012). 
The interface chamber was perfused with ACSF (containing in mM: 119 NaCl, 26 NaHCO3, 10 glucose, 
2.5 KCl, 1 NaH2PO4, 2.5 CaCl2 and 1.3 MgCl2). Temperature of the ACSF was maintained at 32°C and 
slices were incubated for at least 60 min before recordings started. All ACSF solutions were 




Figure 8: Interface chamber for slice storage.  
Brain slices were placed on lens cleaning tissues in the interface chamber. ACSF is transported 
through polyethylene tubing and reaches the lower part of the brain slices. Top parts of brain slices 
are not covered by ACSF. ACSF and water in the interface chamber are oxygenated by carbogen. A: 1) 
Interface chamber containing horizontal hippocampal brain slices; heated to 33°C. 2) Perfusion pump 
for ACSF circulation. 3) Water bath with ACSF (in bottle). B: Higher magnification of interface 
chamber in which ACSF is transported from top to bottom to supply horizontal brain slices. C: 
Schematic drawing of the interface chamber; modified from Haas et al., 1979. Top: Side view. Right: 
View from above. Bottom left: Front view. L: Lid; m: Nylon mesh; p: Prechamber; pl: Projecting part 
of lid; r: Recording chamber; s: Slice; t: Polyethylene tube; ul: Upper lid; w: Ground wires; wa: Water 




2.2.4.1 General setup 
For recordings, individual brain slices were transferred to a submerged chamber, perfused with ACSF 
(~5 ml/min, pre-heated to 33°C in a water bath, in addition heated via a PH01 heatable perfusion 
cannula mounted on the solution inlet into the recording chamber). Cells were visualized with 
infrared differential interference contrast optics on an Olympus BX-51 WI microscope. Patch clamp 
recordings were performed with a MultiClamp 700B amplifier and monitored using an HM1507-3 
oscilloscope. Data were low-pass filtered at 3 kHz, digitized and sampled at 10 - 20 kHz with 16-bit 
resolution using a BNC-2090 interface board (connected to a PCI 6035E A/D board), and recorded in 




2.2.4.2 Whole-cell patch clamp recordings 
Patch pipettes were pulled from filamented borosilicate glass capillaries (outer diameter 1.5 mm, 
inner diameter 1.17 mm) with a DMZ Universal Puller and fire-polished to a final resistance of 2-3 
MΩ for patch clamp recordings. Unless stated otherwise, pipettes were backfilled with filtered 
KMeSO3-based intracellular solution (containing in mM: 130 KMeSO3, 10 KCl, 10 HEPES, 4 NaCl, 4 Mg-
ATP, 0.5 Na-GTP, 5 phosphocreatine; 285 - 290 mOsm, pH was adjusted to 7.3 with KOH). 
Putative hippocampal principal cells (in CA3 and CA1) were identified based on their location in 
stratum pyramidale, their pyramidal shaped soma and a prominent apical dendrite reaching towards 
stratum radiatum. Oriens lacunosum-moleculare (OLM) cells were located in stratum oriens and 
were identified by their spindle-shaped soma. Cortical interneurons were visually differentiated from 
PCs based on two criteria: A lack of apical dendrite projecting towards the pial surface and 
horizontally orientated and spherical shaped somata compared to the pyramidal shaped somata of 
pyramidal cells (PCs).  
All recordings were performed in current-clamp mode. Resting membrane potential and input 
resistance (Rin) were determined directly after establishing the whole-cell configuration. Experiments 
were only performed if cells had a resting membrane potential more hyperpolarized than -55 mV 
(without correction for liquid junction potential) and a series resistance below 25 MΩ. Cells were 
characterized by recording their membrane response and firing pattern by applying hyperpolarizing 
and depolarizing current steps (-200 to + 600 pA, increment: 40 pA, 1 s). 
Hippocampal PC showed a moderate spiking frequency and no pronounced sag-potential. OLM cells 
were identified by their faster spike frequency, their saw-tooth like firing pattern upon mild 
depolarization and a pronounced voltage sag following hyperpolarization. Cortical fast-spiking (FS) 
interneurons showed high frequency AP firing (>200 Hz) with no frequency adaptation. Both cortical 
regular spiking non-pyramidal cells (RSNPCs) and PCs showed moderate spiking frequency (20 - 60 
Hz) and increasing inter-spike intervals during the depolarization step. The AP slope ratio was 
calculated by dividing maximal positive slope with the maximal negative slope of the AP. Series 




2.2.4.3 Substitution experiments 
Different intracellular and extracellular solutions were used in order to determine the ions that 
contribute to SSI in hippocampal principal cells. Whole-cell recordings were performed in CA1 and 
CA3 PCs and long-lasting hyperpolarization was induced by direct CB2R activation using HU-308. 
Recordings with K+-free intracellular solution (containing in mM: 130 CsMeSO3, 10 HEPES, 10 NaCl, 4 
Mg-ATP, 0.5 Na-GTP, 5 Na-Phosphocreatine) were performed in order to analyze the lack of 
intracellular K+ ions on SSI. The involvement of Cl- on SSI was determined by using either high-Cl--
intracellular solution (containing in mM: 135 KCl, 10 HEPES, 4 NaCl, 4 Mg-ATP, 0.5 Na-GTP, 5 Na-
Phosphocreatine) or low-Cl--ACSF (containing in mM: 99 Na-gluconate, 20 NaCl, 25 NaHCO3, 10 
glucose, 2.5 KCl, 1 NaHPO4, 2.5 CaCl2, 1.3 MgCl2). NMDG-based ACSF (containing in mM: 112 NMDG, 
7 Na-ascorbate, 26 NaHCO3, 10 glucose, 2.5 KCl, 1 NaHPO4, 2.5 CaCl2, 1.3 MgCl2) was used to 
determine a reduced Na+-driving force on SSI. 
 
Table 1: Pharmacological compounds used to determine mechanism of hippocampal SSI. 
Name Function Final concentration Supplier 
SCH23390 GIRK channel blocker 10 µM Tocris 
S0859 NBC blocker 10-30 µM Sigma-Aldrich 
Oubaine Na+/K+ ATPase inhibitor 5 µM Tocris 
BAPTA Ca2+- chelator (in patch pipette) 30 mM Tocris 
Bumetanide NKCC inhibitor 10 µM Tocris 
VU0240551 KCC2 inhibitor 10 µM Tocris 
DNDS Cl- channel blocker (in patch pipette) 500 µM Sigma-Aldrich 
Cariporide NHE1 inhibitor 10 mM Tocris 
Rotenone Inhibits complex I of the 
mitochondrial electron transport 
chain 
2.5 µM Tocris 
Cyclopiazonic acid SERCA-ATP inhibitor 30 µM Tocris 






2.2.4.4 Pharmacological agents 
All drugs were purchased from Sigma-Aldrich or Tocris (both Germany). In hippocampal cells, 
experiments were performed in the continuous presence of GABAA and GABAB receptor blockers 
(1μM Gabazine and 1µM CGP55845) to isolate excitatory transmission, and 100 nM NBQX to prevent 
epileptiform activity. Other drugs were either added to the intracellular solution or bath-applied (see 
Table 1). In the case of bath-aplication of the drugs, slices were preincubated for at least 10min 
before SSI induction. Pharmacology targeting the cannabinoid receptors was used to determine the 
involvement of CB1Rs and CB2Rs in SSI in cells of the somatosensory cortex. Agonists and inverse 
agonists were used in concentrations according to literature for preferential activation or 
deactivation of either CB1Rs or CB2Rs (Table 2). 
 
Table 2: Pharmacological tools to study involvement of cannabinoid receptors in cortical SSI. 
Name Function Final 
concentration 






300 nM 21.2 nM > 3 µM (Hanus et al., 
2001) 
HU-308 CB2R agonist 1 µM > 10 µM 22.7 nM (Hanus et al., 
1999) 
SR144258 CB2R inverse 
agonist 
1 µM 400 nM 0.6 nM (Rinaldi-Carmona 
et al., 1998) 
Ly 320135 CB1R inverse 
agonist 
1 µM 220 nM >10 µM (Felder et al., 
1998) 
 
2.2.4.5 Action potential protocols 
The standard action potential (AP) protocol used to elicit SSI consisted of 15 AP trains in hippocampal 
cells and 10 trains in cortical neurons with 50 AP each (750 or 500 APs, respectively, 10 ms inter-
stimulus interval, 20 s inter-train interval). Individual APs were elicited by 2 ms, somatic current 




2.2.4.6 Data analysis 
Data were analyzed in IGOR Pro 6.12 using the IGOR analysis software package Neuromatic. 
Statistical comparisons between groups were performed in Prism 5. Sample sizes are given as the 
number of experiments (n). The input resistance was calculated from a 50 ms average of the steady-
state membrane potential response to a hyperpolarizing test pulse (400 ms, -40 pA). Individual 
membrane potential values (denoted as Vm in figures) were determined from a 10 ms average 
around the detected minimum within a 100 ms time window every 20 s. Baseline membrane 
potential values were calculated as the average of a 2 min baseline (6 values) before the action 
potential induction protocol or drug application. Given Vm values are not corrected for liquid junction 
potential (10 mV; calculated with JPCalcWin; Barry, 1994). 
Changes in membrane potential (Vm) were calculated as relative difference from the baseline Vm by 
subtracting the average Vm over 2 min (starting 60 s after the last AP train, or when Vm reached a 
stable state for agonist-induced hyperpolarization). Changes in input resistance after SSI were 
calculated by normalizing the average input resistance after SSI induction to the average baseline 
input resistance. Cells were classified as responding when Vm was higher than three times the 
standard deviation of the baseline Vm. For average Vm values, responding and non-responding cells 
were analyzed together and given as mean ± SEM, unless otherwise stated. 
For summary time plots of the global membrane potential average, the individual values of all 
experiments were averaged per point in time. Exemplary membrane potential recordings are 
unfiltered raw traces if not indicated otherwise. 
Data distribution was assessed with the D’Agostino and Pearson omnibus normality test. Normally 
distributed datasets were compared using a two-tailed unpaired Student’s t-test. Stated p-values 
refer to comparison of hyperpolarization amplitude (Vm) between different datasets by using 
unpaired Student’s t-test, unless otherwise stated. If datasets were not normally distributed the 
Mann-Whitney test was performed to compare the groups. If more than two groups were compared, 
1-way-ANOVA (Kruskal-Wallis Test) followed by post-hoc Dunnett’s Multiple Comparison Test was 
performed. Error bars correspond to the mean ± SEM in normally distributed datasets or to median 
(25th percentile to 75th percentile) in not-normally distributed datasets. Box plots are shown as 




2.2.5 Immunohistochemistry and morphological reconstruction 
Biocytin-containing intracellular solution (0.1% Biocytin, Sigma-Aldrich, USA) was used for post-hoc 
identification of the recorded neuron. After the recording, brain slices were fixed overnight in 4% 
paraformaldehyde in PBS (pH 7.4) at 4°C. Subsequently the sections were washed three times (10 
min each) in PBS and incubated in a blocking solution composed of 5% normal goat serum (NGS, 
Biozol, Germany), 0.1% Triton-X (Sigma-Aldrich, USA) and PBS for three hours at room temperature 
with gentle agitation. Primary antibodies (mouse anti-GAD67, 1:500; mouse anti-Reelin, 1:1000, 
Millipore, USA) and conjugated streptavidin-Alexa488 (Invitrogen, USA) were diluted in a 2.5% NGS 
blocking solution and sections were incubated for 48 hours at 4°C. Following this, sections were 
washed three times (10 min each) with PBS and secondary antibodies (goat anti-mouse Alexa647, 
Life Technologies, USA) were applied, diluted to 1:500 in PBS for 3 hours at room temperature. 
Finally, slices were washed 4 times (10 min each) before being mounted on glass slides in mounding 
medium (Mowiol, Sigma-Aldrich, USA). 
Stained slices were imaged with a laser confocal microscope (Leica DMI 6000) using a 20x or 63x 
objective and a z-step size of 1 µm. Morphological reconstruction was performed using Neutube 






3.1 Hippocampal SSI 
3.1.1 Mechanism underlying SSI in hippocampal PCs 
Brief trains of APs induce CB2R-mediated SSI in hippocampal PCs (Figure 7A), which can be mimicked 
by application of the selective CB2R agonist HU-308 (Stempel et al., 2016). Unlike in cortical SSI (Bacci 
et al., 2004; Marinelli et al., 2009), this hyperpolarization is not accompanied by a decrease in input 
resistance (Figure 7C; Stempel et al., 2016). The input resistance of a cell describes the reciprocal 
value of its conductance. A change in conductance of the cell membrane is usually linked to opening 
or closing of ion channels, in case of cortical SSI opening of GIRK channels (Bacci et al., 2004).  
Since the input resistance remains unchanged during CB2R mediated hyperpolarization in CA3, it is 
unlikely that modulation of ion channels represent the underlying mechanism, suggesting the 
involvement of a different mechanism underlying hippocampal SSI. One putative explanation is the 
activation of an electrogenic ion transporter for CB2R-driven hyperpolarization of the cell. In contrast 
to ion channels, ion transporters can perform an active transport of ions across a cell membrane by 
moving ions against their electrochemical gradient. To overcome this gradient, ion transporters need 
to consume energy, such as ATP (primary transporters) or a concentration gradient of a different ion 
(secondary transporters).  
Due to the high number of potential targets we performed a screening approach using 
pharmacological inhibitors of key molecules of different transduction pathways to abolish SSI. In this 
approach we used either AP trains or direct CB2R activation to elicit the long-lasting 
hyperpolarization in the presence of different inhibitors. If we were able to elicit the long-lasting 
hyperpolarization in at least one recording (> 30% responding cells), we considered the given 
manipulation as not relevant for SSI. A cell was considered to be responding, if the AP- or agonist 
induced hyperpolarization was higher than three times the standard deviation of the baseline 
(dashed line in Figure 9A, B, E). 
In a first attempt to demonstrate that an active ion transport is the underlying expression mechanism 
of hippocampal SSI, we used several approaches to alter the energy metabolism of the recorded 
neurons. After hydrolysis of ATP to ADP, ATP has to be regenerated to serve as an energy source for 
a variety of ion pumps. Phosphocreatine acts as a temporal energy buffer in cells to promote rapid 
regeneration of ATP (Guimarães-Ferreira, 2014). However, when we used an intracellular solution 
without ATP and phosphocreatine added, we could still elicit SSI (Figure 9A). Next, we preincubated 
the slices with cyclopiazonic acid (CPA 30 µM, inhibitor for Sarcoplasmic/endoplasmic reticulum Ca2+-
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ATPase: SERCA) or rotenone (2.5 µM, a mitochondiral electron transport chain inhibitor) to inhibit 
ATP production. However, it was still possible to elicit long-lasting hyperpolarization in presence of 
these drugs (Figure 9A; Table 3), suggesting an ATP-independent mechanism. Hence, it seemed 
unlikely that an active form of ion transport is the underlying mechanism for SSI. 
Since our data indicated that SSI is independent of ATP as an energy source, we hypothesized that a 
secondary ion transporter might be activated during the induction of SSI. To delimit the ion pumps 
that could be the target of CB2R activation we performed substitution experiments (Figure 9B, C): We 
removed individual ions from the extracellular or the intracellular solutions in order to abolish the 
ion gradient across the cell membrane and prevent the induction of the long-lasting 
hyperpolarization. Substitution of extracellular Cl- (with Na+-gluconate) or increase of intracellular Cl- 
(by a KCl-based intracellular solution) as well as removing intracellular K+ ions (with a CsMeSO3-based 
intracellular solution) did not block long-lasting hyperpolarization (Figure 9B, C). In fact, by reducing 
the K+ gradient, the amplitude of the long-lasting hyperpolarization seemed to increase. However, 
replacing Na+ with NMDG completely abolished the agonist-induced hyperpolarization (Figure 9B, D; 
Table 3), indicating that the Na+ gradient across the cell membrane is necessary to establish the long-
lasting hyperpolarization. 
To determine the identity of the specific transporter that mediates hippocampal SSI, we performed a 
set of experiments in which we pharmacologically deactivated several ion pumps. Thus, we blocked 
the Na+/K+/Cl- transporter NKCC (with 10 µM bumetanide), the Na+/H+ exchanger (with 10 µM 
cariporide), the Na+/K+ ATPase (with 10 µM Ouabain), the K+/Cl- transporter KCC2 (with 10 µM 
VU0240551) and anion transporters (with 500 µM DNDS, in the patch pipette). However, we could 
not antagonize the long-lasting hyperpolarization (Figure 9E, F; Table 3). In contrast, a specific 
blocker of the electrogenic Na+/bicarbonate transporter (NBC; antagonized with S0859 10-30 µM) 




Figure 9: Mechanism underlying hippocampal SSI. 
A: Different attempts to manipulate the cellular energy metabolism failed to block SSI induction. 
Dashed line: Approximate threshold for successful SSI induction (three times the standard deviation 
of the baseline). B - D: Removal of individual ions showed that substitution of extracellular Na+ ions 
by NMDG blocked the long-lasting hyperpolarization whereas it was still present in the absence of a 
K+ or Cl- gradient. B: Amplitude of long-lasting hyperpolarization; C: Occurrence of long-lasting 
hyperpolarization. D: Time course of agonist induced long-lasting hyperpolarization in NMDG-
containing and control ACSF solutions. E - F: Pharmacological inactivation of several ion transporters 
showed no effect on HU-308-induced long-lasting hyperpolarization. Amplitude (E) and occurrence 
(F) of HU-308-induced long-lasting hyperpolarization in presence of different ion transporter 
inhibitors. 
 
In order to get more insight on the intracellular mechanism linking the AP trains with the activation 
of the NBC, we performed a series of experiments in which we added the Ca2+ chelator BAPTA into 
the intracellular solution. It is well-known that an intracellular Ca2+ increase can lead to the 
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production of endocannabinoids, thus interfering with the intracellular Ca2+ signal should prevent 
this process (Ohno-Shosaku et al., 2001). In line, SSI was abolished when recordings were performed 
with BAPTA-containing (30 mM) intracellular solution, indicating a Ca2+-dependent mechanism for 
establishment of the long-lasting hyperpolarization (Figure 11A, C). However, a transient 
hyperpolarization was still present during the induction trains, but the membrane potential returned 
to baseline as soon as the AP trains stopped (Figure 11A). Interestingly, disruption of intracellular 
Ca2+ signaling also prevented CB2R agonist-induced long-lasting hyperpolarization, indicating a Ca
2+-
dependent mechanism downstream of CB2R activation for SSI (Figure 11B, C). 
 
 
Figure 10: Deactivation of the NBC prevented both AP trains and agonist-induced long-lasting 
hyperpolarization.  
A - B: Average time course of cells that were preincubated with the NBC antagonist S0859 (10-30 
µM). AP trains (A) and application of HU-308 (B) did not induce a long-lasting hyperpolarization. C: 
Individual display of Vm for the two conditions of SSI-induction in presence of the NBC blocker 
S0859. 
 
Together, these results demonstrate that (1) hippocampal SSI is dependent on the Na+ gradient 
across the cell membrane, and (2) that the hyperpolarization is mediated via NBC that are activated 
after ligand binding to CB2Rs. These results have been published as part of the manuscript entitled 
“Cannabis Type 2 Receptors Mediate a Cell Type-Specific Plasticity in the Hippocampus” (Stempel et 




Figure 11: Intracellular Ca2+ signaling is necessary for induction of both AP train and agonist-
induced hyperpolarization.  
A - B: Average time course of changes in membrane potential for cells recorded with BAPTA (30 mM) 
containing intracellular solution. Intracellular BAPTA abolished the induction of the long-lasting 
hyperpolarization by AP trains (A) and HU-308 (B). AP trains induced a transient hyperpolarization 
during the induction. C: Individual display of Vm for the two conditions of SSI-induction in presence 
of intracellular BAPTA. BAPTA + APs: n = 24; BAPTA + HU-308: n = 13.  
 
To conclude, SSI in hippocampal CA3 PCs is mediated by CB2Rs that activate the NCB transporter (via 
a still unknown intracellular signal cascade). Thus, hippocampal SSI is established by a mechanism 
that does not affect the input resistance, which is in contrast to cortical neurons, where SSI depends 
on the activation of GIRK channels downstream of cannabinoid receptors (Bacci et al., 2004; Marinelli 





Table 3: Amplitude and occurence of SSI in hippocampal PC under different recording conditions 
 Nr. of experiments Average Vm (mV) Responding cells 
“No ATP” intra 2 -3.02 ± 0.37 2/2 
“NoPhosphocreatine” intra 3 -6.02 ± 2.83 3/3 
CPA 5 -3.44 ± 1.80 3/5 
Rotenone 3 -0.69 ± 1.89 1/3 
ACSF 20 -3.60 ± 0.98 10/20 
CsMeSO4 Intra 3 -13.28 ± 3.95 3/3 
Na-Gluconate ACSF 3 -4.95 ± 2.71 2/3 
KCl Intra 4 -2.84 ± 1.51 2/4 
NMDG ACSF 12 -0.51 ± 0.34 2/12 
VU0240551 3 -5.663 ± 2.74 2/3 
Bumetanide 6 -2.10 ± 1.94 3/6 
Cariporide 4 -4.29 ± 2.32 3/4 
Ouabain 14 -2.78 ± 1.33 5/14 
DNDS 5 -6.94 ± 3.57 4/5 
S0859 + APs 24 1.17 ± 0.47 1/24 
S0859 + HU-308 16 -0.27 ± 0.50 2/16 
BAPTA + APs 24 0.32 ± 0.46 5/24 
BAPTA + HU-308 13 0.99 ± 0.70 1/13 
Average Vm values are given as mean ± SEM including responding and non-responding cells. 
 
3.1.2 SSI in OLM cells 
We have demonstrated that hippocampal CA3 pyramidal cells show a long-lasting hyperpolarization 
after brief AP firing (Figure 7A; Stempel et al., 2016) that is mediated by CB2R activation. In contrast, 
CA1 PCs did not show SSI after AP trains, but still hyperpolarized after direct CB2R activation with the 
specific agonist HU-308 (Stempel, 2015; Stempel et al., 2016), indicating CB2R expression. 
Additionally, granule cells of the dentate gyrus did not hyperpolarize with both induction protocols 
(Stempel, 2015; Stempel et al., 2016). Thus, in the hippocampus SSI was so far only identified in a 
subset of excitatory neurons. In light of these findings, two questions arose: 1) Is SSI also present in 




To analyze the occurrence of SSI in inhibitory cells, we investigated hippocampal oriens lacunosum-
moleculare (OLM) interneurons that have a distinctive location, firing pattern and morphology. OLM 
interneurons are somatostatin-expressing cells (Forro et al., 2015) that are located in stratum oriens 
of the hippocampus. The axons of OLM cells project towards stratum lacunosum-molaculare (verified 
in post-hoc biocytin staining, Figure 12A). In addition, OLM cells can be identified by their saw-tooth 
like firing pattern upon mild depolarization (Pangalos et al., 2013; Figure 12A). In line with previous 
studies (Pangalos et al., 2012), the input resistance of the recorded OLM cells was on average 377.2 ± 
37.4 MΩ (data not shown), supporting the identity of the recorded cells as OLM interneurons. 
 
 
Figure 12: SSI is not present in hippocampal OLM cells.  
A: Morphological reconstruction and firing pattern (inset: Scale bar: 0.1 s/20 mV) of biocytin-filled 
OLM cell. Scale bar: 50 µm. Spindle-shaped somata of OLM cells are located in stratum oriens (so) 
and axons project through stratum pyramidale (sp) and stratum radiatum (sr) towards stratum 
lacunosum-moleculare (slm) and ramify in slm (asterisk). B - C: Average membrane potential of OLM 
cells during AP trains (black lines, B) and agonist HU-308 application (black bar, C). D: individual 
amplitudes of hyperpolarization. AP trains and HU-308 application did not lead to a long-lasting 
hyperpolarization in OLM cells. APs: n = 6; HU-308: n = 9. 
 
Trains of APs did not elicit SSI in OLM cells (Figure 12B, D). Additionally, application of the CB2R 
agonist HU-308 did not change the membrane potential of OLM cells (Figure 12C, D) suggesting a lack 
of CB2Rs or the downstream transduction pathway for SSI in this cell type. To summarize, OLM cells 
that were analyzed as an example of an inhibitory cell type hippocampus showed no 
hyperpolarization after activation with AP trains of pharmacological CB2R activation.  
In the hippocampus, expression of SSI was only found in a subset of excitatory cells (CA3 and CA2 PCs 
but not in CA1 PCs and dentate gyrus granule cells; Stempel et al., 2016). In these cells, SSI was 
exclusively induced by CB2R activation. Remarkably, up to this point, it remained unclear whether in 
cortical neurons only CB1Rs mediate SSI, or whether CB2Rs also contribute to its induction. 
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Furthermore, it was not clear if all or just a subset of cortical neurons, can express SSI, and by which 
mechanism it is implemented. Therefore, in the final part of my PhD project, I investigated the 
expression and underlying mechanism of SSI in different neurons of the somatosensory cortex 
(chapter 3.2). 
 
3.2 Cortical SSI 
Our findings show that hippocampal SSI differs from the previous description of cortical SSI (Bacci et 
al., 2004; Marinelli et al., 2009) in terms of utilization of the cannabinoid receptor type and its 
downstream mechanism implementing the long-lasting hyperpolarization. Hence, we were 
wondering whether the establishment of SSI is, in fact, so variable in different celltypes and brain 
regions, or if we could identify similarities. 
 
3.2.1 Cell type-specific expression of SSI in cortical neurons 
In order to further investigate SSI induction and expression in different cell types, we performed 
whole-cell patch clamp recordings in three types of cortical neurons in the somatosensory cortex 
layer 2/3: Pyramidal cells (PCs), regular spiking non-pyramidal cells (RSNPCs) and fast-spiking 




Figure 13: Morphological and electrophysiological properties of the three recorded cell types in the 
somatosensory cortex. 
Characteristic cell morphology and firing pattern of a PC (A), a RSNPC (B) and a FS (C), visualized by 
post-hoc biocytin staining and morphological reconstruction. Scale bar: 50 µm; arrow head depicts 
the direction of the pial surface. Insets show neuron type-specific firing pattern evoked by 
depolarizing current injection. Scale bars: 0.2 s/20 mV. 
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PCs showed a typical, eponymous pyramid-shaped cell soma, a prominent apical dendrite exceeding 
the pyramidal layer towards the pial surface (Figure 13A) and a regular firing pattern (Table 4). The 
firing pattern of RSNPCs was undistinguishable from PCs (Table 4); however, their horizontally 
orientated and spherical soma shape (Figure 13B) allowed clear discrimination between the two cell 
types. Finally, FSs also displayed a characteristic firing pattern (Table 4) and a non-pyramidal soma 
shape without an apical dendrite projecting towards the pial surface (Figure 13C). FSs also showed a 
depolarized resting membrane potential and a smaller input resistance compared to regular firing 
cells (Table 4). Additionally, AP half-widths and AP slope ratio were smaller and AP threshold was 
detected at more depolarized membrane potentials in FSs. Lastly, FSs were able to fire at much 
higher frequencies compared to regular spiking cells (Table 4). 
 
Table 4: Cell properties of cortical neurons in somatosensory cortex layer 2/3 
 PCs (11) RSNPCs (21) FSs (6) 
Resting membrane potential [mV] -81.9 ± 2.0 -80.6 ± 1.2 
 
-65.2 ± 1.9 
Input resistance [MΩ] 153.1 ± 11.6 189.3 ± 13.9 80.6 ± 9.7 
AP half-width [ms] 1.0 ± 0.1 1.6 ± 0.1 0.3 ± 0.2 
AP threshold [mV] -33.9 ± 1.3 -36.0 ± 1.0 -46.8 ± 2.6 
AP slope ratio 4.5 ± 0.2 4.5 ± 0.2 0.9 ± 0.1 
AHP [mV] -16.7 ± 0.7 -15.0 ± 0.5 -18.1 ± 0.6 
Maximal firing frequency [Hz] 36.8 ± 2.3 41.17 ± 2.3 360 ± 39.9 
Values are given as mean ± SEM, PCs: Pyramidal cells; RSNPCs: Regular spiking non-pyramidal cells; 
FSs: Fast spiking interneurons; AHP: Afterhyperpolarization; numbers of recorded cells are displayed 




Figure 14: Trains of APs elicit a cell type-specific hyperpolarization.  
AP trains induce SSI in PCs (A, D, G, n = 11) and RSNPCs (B, F, H, n = 21) but not in FSs (C, E, I, n = 6).  
A - C: Example trace of SSI induction in different cell types. Scale bar: 0.1 s/5 mV. D - F: Average 
membrane potential before during and after SSI induction. G - I: Hyperpolarization amplitudes in 
different cell types. AP trains are depicted as black lines. 
 
In these three cell types, we intended to induce SSI by eliciting AP trains with 2 ms long somatic 
current injection (10 AP trains, 20 s inter-train interval; 50 APs/train at 100 Hz). Trains of APs elicited 
long-lasting SSI in PCs (Figure 14A, D, G; Vm: -4.1 ± 1.5 mV) and in RSNPCs (Figure 14B, E, H; Vm : -
5.6 ± 1.1 mV), but not in FSs (Figure 14C, F, I; Vm: -0.7 ± 0.5 mV). It was shown before that in whole-
cell recordings only subsets of cell respond to the SSI-inducing stimulus: In hippocampal CA3 PC 50-
60% showed a long-lasting hyperpolarization (Table 3; Stempel et al., 2016); 78% of layer 5 LTS-
Interneurons (Marinelli et al., 2008) and 26-30% of layer 2/3 PC (Marinelli et al., 2009). We 
considered a cell as responding if Vm after SSI induction was larger than three times the standard 
deviations of the baseline membrane potential. Accordingly, 73 % (8/11) of PCs and 71% (15/21) of 
RSNPCs exhibited a significant hyperpolarization after AP trains, whereas none of the FS were 
responding. Here, both responding and non-responding cells were included in averaged values and 
statistics (Figure 14). Taking into account only responding cells, PCs hyperpolarize by -6.0 ± 1.6 mV 





Figure 15: Responding and non-responding RSNPCs to SSI inducing AP trains. 
Trains of AP induced a long-lasting hyperpolarization in the majority of RSNPCs while a subset of cells 
maintained a constant membrane potential. A: Amplitude of hyperpolarization after AP trains. B: 
time course of hyperpolarization in response to AP trains (black lines) in responding (black circles, n = 
15) and non-responding (open circles, n = 6) RSNPCs. 
 
In an additional set of experiments, we analyzed multiple parameters of the APs during the cell type 
characterization and found that they were both stable and of comparable magnitude in responding 
and non-responding cells (Figure 16). A notable difference was only observed in the AP half-width in 
RSNPCs (measured at 50% of maximum amplitude), which was shorter in cells that did not respond 
with SSI to the induction-trains (Figure 16H; responding: 1.8 ± 0.1 ms vs. non-responding: 1.3 ± 0.1 
ms; p = 0.0012). In PCs the AP half-width also showed a tendency to shorter values in non-responding 
cells, but the difference to cells with SSI was not significant (Figure 16 D; responding: 1.2 ± 0.1 ms, vs. 
non-responding: 1.1 ± 0.1 ms; p = 0.26 n.s.). 
Additionally, we analyzed the properties of the induction trains in the different cell types as well as in 
responding and non-responding cells. In each case there were no failures of APs nor substantial 





Figure 16: AP properties of responding and non-responding PCs and RSNPCs.  
Several active properties were analyzed in PCs (responding: n = 30; non-responding: n = 8) and 
RSNPCs (responding: n = 33; non-responding: n = 13) during cell characterization (1 s depolarization 
step). H: Responding RSNPCs showed higher AP half-width compared to non-responding cells (p = 
0.0012, Student’s t-test). All other parameters analyzed did not show any significant differences 
between responding and non-responding cells. 
 
 
Figure 17: AP trains for SSI induction in responding and non-responding cells of different cell types.  
Induction trains (50 APs, 100 Hz) show stable responses with no failures or substantial declines in AP 
amplitude throughout the trains. Scale bars: 0.1 /20 mVs.  
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An additional group of cells showed different firing patterns during characterization (Figure 18A), 
distinct from RSNPCs, PCs and FSs. These firing patterns were similar to those reported for 
somatostatin-expressing interneurons (Jiang et al., 2015). Characterization of somatostatin 
interneurons in a somatostatin-Cre/Ai9 reporter mouse line (Madisen et al., 2010; Taniguchi et al., 
2011) supported the assumption that these cells represent somatostatin-expressing interneurons 
(Figure 18B). In WT animals, trains of APs did not elicit SSI in these putative somatostatin 
interneurons (Figure 18C, D). 
 
 
Figure 18: Putative somatostatin-expressing cells do not express SSI.  
A: Characteristic AP firing pattern of putative somatostatin-expressing interneurons in BL6/N mice. B: 
Immunohistochemical image of Ai9 x somatostatin reporter mouse: tdTomato is expressed under the 
somatostatin-promoter (red). Patched cells were filled with biocytin and visualized with streptavidin 
conjugated with Alexa 488 (green). Scale bar: 100 µm. C: Average membrane potential of putative 
somatostatin cells in WT animals before, during and after SSI induction. D: Hyperpolarization 
amplitudes elicited by AP trains. n = 7. 
 
Further, we characterized the properties of the established hyperpolarization after SSI induction in 
RSNPCs. After SSI-inducing AP trains, the cells remained stably hyperpolarized during the entire time 
of the recording (up to 40 minutes) and we did not observe a rundown of the SSI effect (Figure 19A). 
This persistency of the long-lasting hyperpolarization was also observed in CA3 PCs (Stempel et al., 
2016), in LTS interneurons (Bacci et al., 2004) and in PCs (Marinelli et al., 2009) in the somatosensory 
cortex after SSI induction. In another set of experiments, we elicited two additional trains of APs 
after successful induction of SSI, with an interval of several minutes between those applications 
(Figure 19B, C). The initial first train was sufficient to maximally evoke SSI and subsequent trains did 




Figure 19: Characterization of SSI in RSNPCs.  
A - B: Average time-course of membrane potential in RSNPCs before during and after SSI induction. 
Black lines depict trains of AP. A: One SSI-inducing AP train hyperpolarizes the cell long-lastingly for 
up to 40 min. 0 - 23 min: n = 7; 23 - 28 min: n = 6; 28 - 33 min: n = 5; 33 - 38 min: n = 4; 38 - 44 min: n 
= 3.B - C: Additional AP trains do not lead to any further hyperpolarization. C: Hyperpolarization 
amplitudes compared to baseline before first AP train. 1) n = 8; 2) n = 8; 3) n = 7. 
 
3.2.2 Mechanism underlying cortical SSI in RSNPCs 
We have previously shown that trains of APs induce a cell-autonomous CB2R-dependent SSI in 
hippocampal PCs by activation of a Na+/bicarbonate cotransporter (NBC; chapter 3.1; Stempel et al., 
2016). In contrast, both layer 2/3 PCs and layer 5 interneurons of the somatosensory cortex were 
suggested to utilize an alternative mechanism in which activation of CB1Rs induces a GIRK channel-
driven hyperpolarization (Bacci et al., 2004; Marinelli et al., 2009). 
The cellular mechanisms of SSI have not been characterized before in layer 2/3 RSNPCs, despite the 
fact that of all cells in layer 2/3, RSNPCs show the most pronounced SSI (Figure 14). Thus, we focused 
on RSNPCs to further investigate the SSI mechanism: In RSNPCs, the magnitude of hyperpolarization 
correlated with the decrease in input resistance (Figure 20A), indicating an increase in ion channel 
conductance. Preincubation with an inhibitor of NBC (10 µM S0859) did not alter SSI in RSNPCs 
(Figure 20B, C, DVm: -4.4 ± 0.9 mV; 11/13 responding cells).  
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In contrast, preincubation with a GIRK channel blocker (10 µM SCH23390) prevented the long-lasting 
hyperpolarization (Figure 20B, D; control Vm: -5.6 ± 1.1 mV; 15/21 responding cells; SCH23390 Vm: 




Figure 20: SSI is mediated via GIRK channels.  
A: The amplitude of the hyperpolarization (Vm) correlates with the reduction in input resistance 
(normalized to pre-AP average; r² = 0.81, p < 0.0001). Inset: example traces of -40 pA test pulses 
before and after AP trains. Scale bar: 0.2s/5 mV; filled circle in the plot depicts recording for example 
traces. B: Preincubation with the GIRK blocker SCH23390 (10 µM) abolished SSI whereas SSI was still 
intact in the presence of the NBC antagonist S0859 (10 µM). C: SCH23390 reduced the average SSI 
magnitude (1-way-ANOVA: p = 0.0001; Dunnett’s Multiple comparison Test: *** control vs 
SCH23390) and percentage of hyperpolarizing cells (D), while S0859 had no effect on cortical SSI. 
Control: n = 21; S0859: n = 13; SCH23390: n = 11. 
 
Application of SCH23390 after SSI induction strongly depolarized the cells and increased input 
resistance (test pulse amplitude returns to baseline amplitude after SCH23390 application, Figure 
21A), reversing the AP-induced effects (Figure 21A, B). In contrast, only a weak baseline 
depolarization occurred when SCH23390 was applied to non-stimulated RSNPCs (Figure 21C). Thus, 
the AP-induced hyperpolarization in RSNPCs is mediated via activation of GIRK channels and not by 






Figure 21: Application of GIRK-channel blocker reverses SSI.  
A: Single cell example of the depolarization induced by SCH23390 (10 µM) after SSI induction. Black 
lines depict AP train, black bar represents SCH23390 application. Scale bar: 5min/ 5 mV. Inset: higher 
magnification of test pulses (40 pA) to determine input resistance. Membrane potentials: 1) Baseline 
(-61 mV); 2) SSI (-76 mV); 3) SCH23390 (-54 mV). Scale bar: 0.1 s/ 5mV B: Single membrane potential 
values before SSI induction (baseline), after AP train (SSI) and after application of SCH23390 (n = 5). 
C: Application of SCH23390 on non-stimulated cells (on baseline) causes only a minor depolarization 
compared to the effect after SSI (p = 0.0159, Mann-Whitney test; On baseline: n = 4; After SSI: n = 5).  
 
3.2.3 Pharmacological investigation of the cannabinoid receptor involved in SSI of 
RSNPCs 
SSI was previously characterized as an endocannabinoid-dependent mechanism in which either 
CB1Rs (Bacci et al., 2004; Marinelli et al., 2009) or CB2Rs (Stempel et al., 2016) induce a long-lasting 
hyperpolarization after periods of AP firing, via different mechanisms. In order to identify the 
responsible cannabinoid receptor in RSNPCs we applied specific agonists for the two receptor types. 
In neocortical RSNPCs, the specific CB2R agonist HU-308 (1 µM) mimicked the AP-induced 
hyperpolarization, whereas application of the endocannabinoid noladin ether (300 nM), which 
displays selectivity for CB1Rs over CB2Rs (Hanus et al., 2001), did not cause a hyperpolarization 
(Figure 22; Vm represent median (25
th percentile to 75th percentile): HU-308Vm: -4.8 mV (-9.4 mV 




Figure 22: CB2R specific agonist mimics long-lasting hyperpolarization.  
A: Time course of average membrane potential in response to application of the specific CB2R agonist 
HU-308 (1µM) and the endocannabinoid noladin ether (300 nM) that displays selectivity for CB1Rs 
over CB2Rs. Agonist application is indicated by the black line. B: Individual magnitudes of agonist-
induced hyperpolarization. Noladin ether does not cause a hyperpolarization, while HU-308 mimics 
SSI (** p = 0.005, Mann-Whitney test; HU-308: n = 10; NE: n = 11); error bars represent median with 
interquartile range. C: Percentage of cells in which drug application evoked hyperpolarization. 
 
To further substantiate the assumption of a shared CB2R dependent mechanism in AP train and 
agonist-induced hyperpolarization, we performed occlusion experiments. When HU-308 was applied 
after successful SSI induction in RSNPCs, the agonist failed to further hyperpolarize the membrane 
potential (Figure 23A, D). The same effect occurred when the induction protocols were applied in the 
reverse order (AP trains after HU-308 application) supporting the finding that both procedures are 
acting via CB2Rs to activate the same cellular mechanism (Figure 23B, E). As a control, we performed 
the occlusion experiment for CB1R activation: CB1R activation by noladin ether application (300 nM) 
failed to induce a long-lasting hyperpolarization and subsequent AP trains lead to SSI induction 
(Figure 23C, F). To conclude, activation of CB2Rs (via AP trains or agonist application) leads to a long-
lasting hyperpolarization that does not lead to an additional hyperpolarization after further 
stimulation with CB2R-activating stimuli. However, if CB1Rs are activated by noladin ether, it is still 





Figure 23: Occlusion of SSI induction by AP trains and cannabinoid receptor agonists.  
A - C: Time course of average membrane potential. D - F: Individual magnitudes of hyperpolarization 
after agonist application or AP train. A, D: SSI induction by AP trains (black lines) occludes further 
hyperpolarization via CB2R activation by HU-308 (1 µM, black bar) and vice versa (B, E). C, F: CB1R 
activation by noladin ether (300 nM, black bar) did not lead to a significant hyperpolarization. 
Subsequently, SSI could be still elicited by AP trains (black lines). F: Mann-Whitney-test p = 0.0496. 
APs/HU-308: n = 5; HU-308/APs: n = 5; Noladin ether/APs: n = 5. 
 
After demonstrating that CB2R activation is sufficient to induce SSI, we focused the next series of 
experiments on investigating whethert CB2Rs are also necessary for SSI induction. Preincubation with 
cannabinoid receptor inverse agonists SR144528 (1 µM, CB2R inverse agonist) or LY320135 (1µM, 
CB1R inverse agonist) reduced the magnitude of SSI (Figure 24A, B; Vm represent median (25
th 
percentile to 75th percentile): control Vm= -6.7 mV (-9.2 mV to -1.0 mV); Ly320135 Vm= -2.0 mV (-





However, only the antagonization of CB2Rs lead to a reduction in SSI occurrence, since the 
percentage of responding cells was comparable between LY320135 preincubated cells and control 
conditions (Figure 24C; control: 15/21 responding cells; SR144258: 3/15 responding cells; Ly320135: 
14/19 responding cells). Although we cannot completely exclude a role of CB1Rs in SSI induction, the 
pharmacological experiments suggest that CB2Rs are mainly responsible for SSI in RSNPCs. 
 
 
Figure 24: Inverse agonists for CB1R and CB2Rs reduce SSI.  
A: Time course of average membrane potential before, during (Black lines) and after AP trains in 
presence or absence of cannabinoid receptor inverse agonists (Ly320135: CB1R inverse agonist, 1 µM; 
SR144259: CB2R inverse agonist, 1 µM). B: Individual magnitudes of AP-induced hyperpolarization in 
the presence of cannabinoid receptor inverse agonists. Error bars correspond to median with 
interquartile range. Both inverse agonists reduced the magnitude of SSI (1-way-ANOVA: ** p = 0.005; 
Dunn’s Multiple Comparison Test: control vs. Ly320135 *; control vs. SR144258 **; control: n = 21; 
Ly320135 n = 19; SR144258: n = 15) but only SR144258 reduced its occurrence. C: Percentage of cells 
in which AP trains evoked hyperpolarization. Error bars represent median with interquartile range. 
 
3.2.4 Characterization of the cannabinoid receptor responsible in cortical SSI by use of 
specific knockout mice 
In order to verify the major role of CB2Rs in cortical SSI, we used transgenic KO mice lacking CB1R or 
CB2R and their corresponding littermates (Buckley et al., 2000; Zimmer et al., 1999) to further 
corroborate the involvement of the major cannabinoid receptors in AP-induced SSI. In both CB1R KO 
mice and WT littermates, trains of APs elicited a long-lasting hyperpolarization of similar magnitude 
in RSNPCs (Figure 25A - C; CB1R KO: Vm: -3.7 ± 0.9 mV, 12/17 responding cells; CB1R WT: Vm: -5.2 ± 
1.5 mV, 7/10 responding cells).  
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In contrast, CB2R-deficient mice showed a marked reduction of SSI, both in the SSI amplitude (Figure 
25D, E; CB2R KO: Vm: -0.4 ± 0.6 mV; CB2R WT: Vm: -3.6 ± 0.8 mV) as well as in the number of 
responding cells (Figure 5F; CB2R KO: 2/12; CB2R WT: 9/12). 
 
 
Figure 25: AP-induced hyperpolarization in RSNPCs is absent in CB2R-deficient mice but present in 
CB1R-deficient mice.  
A - C: AP train-induced SSI in RSNPCs of CB1R-deficient mice is indistinguishable from SSI in WT-
littermates (p = 0.4 Student’s t-test; CB1R KO n = 17; CB1R WT n = 10). A: Time course of the average 
membrane potential in WT (open circles) and CB1R KO mice (black circles). B: Overview on individual 
magnitudes of AP-induced hyperpolarization. C: Percentage of cells in which AP trains evoked 
hyperpolarization. D - F: Trains of APs failed to induce SSI in CB2R-deficient mice compared to WT-
littermates (** p = 0.003 Student’s t-test; CB2R KO n = 12; CB2R WT n = 12). D: Time course of the 
average membrane potential in WT (open circles) and CB2R KO mice (black circles). E: Overview on 
individual magnitudes of AP-induced hyperpolarization. F: Percentage of cells in which AP trains 




Corresponding phenotypes were also observed in recordings of PCs in transgenic cannabinoid 
receptor KO animals: in CB1R-deficient mice and their WT littermates trains of APs induced SSI of 
similar magnitude (Figure 26A - C; Vm represent median (25
th percentile to 75th percentile): CB1R 
WT: Vm: -2.7 mV (-5.6 mV to -1.9 mV); 10/12 responding cells; CB1R KO: Vm: -4.3 mV (-7.2 mV to -
0.1 mV), 7/12 responding cells).  
 
 
Figure 26: AP-induced hyperpolarization in PCs is absent in CB2R-deficient mice but present in CB1R-
deficient mice.  
A - C: AP train-induced SSI in RSNPCs of CB1R-deficient mice is indistinguishable from SSI in WT-
littermates (p = 0.93 Mann-Whitney test; CB1R KO n = 12; CB1R WT n =12). A: Time course of the 
average membrane potential in WT (open circles) and CB1R KO mice (black circles). B: Overview on 
individual magnitudes of AP-induced hyperpolarization. C: Percentage of cells in which AP trains 
evoked hyperpolarization. D - F: Trains of APs failed to induce SSI in CB2R-deficient mice compared to 
WT-littermates (** p = 0.004 Mann-Whitney test; CB2R KO n = 15; CB2R WT n = 15). D: Time course of 
the average membrane potential in WT (open circles) and CB2R KO mice (black circles). E: Overview 
on individual magnitudes of AP-induced hyperpolarization. F: Percentage of cells in which AP trains 




In contrast, the genetic deletion of CB2Rs abolishes SSI also in PCs (Figure 26 D - F; Vm represent 
median (25th percentile to 75th percentile): CB2R WT: Vm: -4.7 mV (-8.6 mV to -2.2 mV), 11/15 
responding cells; CB2R WT: Vm: -0.6 mV (-1.9 mV to 1.5 mV), 4/15 responding cells). Thus, CB2R 
dependence of cortical SSI may represent a general phenomenon that is expressed in different cell 
types. 
Finally, we tested the specificity of the CB2R agonist HU-308 for inducing a long-lasting 
hyperpolarization in RSNPCs. In CB1R-deficient mice as well as in their corresponding littermates, HU-
308 application mimicked AP-induced SSI while it failed to hyperpolarize RSNPCs in CB2R-deficient 
mice (Figure 27; CB1R KO: Vm: -4.9 ± 1.9 mV, 7/10 responding cells; CB1R WT: Vm: -5.5 ± 1.7 mV, 
7/10 responding cells; CB2R KO: Vm: 0.5 ± 0.5 mV, 0/8 responding cells; CB2R WT: Vm: -4.1 ± 1.8 
mV, 7/11 responding cells). These experiments rule out potential off-target effects of HU-308 in the 
induction of SSI and underline its specificity for CB2R at a concentration of 1 µM. 
 
 
Figure 27: CB2R agonist mimics SSI in CB1R deficient mice but not in CB2R KO animals. 
 A: Exemplary time course of the membrane potential of RSNPCs in response to HU-308 application 
(black line). Note the hyperpolarization in the CB1R KO (black circles), and the lack of 
hyperpolarization in the CB2R KO (black squares). B: Individual magnitudes of agonist-induced 
hyperpolarization in different genotypes. HU-308 (1 µM) hyperpolarized RSNPCs in CB1R deficient 
mice and WT-littermates of transgenic animals (CB1R KO n = 10; CB1R WT n = 10), but not in CB2R-
deficient mice (p = 0.046 Student’s t-test; CB2R KO n = 8; CB2R WT n = 10). C: Percentage of cells in 




3.2.5 Identity of RSNPCs 
In order to further understand the physiological role of SSI, it is of major importance to know the 
physiological function of the cell types that express SSI. As the RSNPCs are an ill-defined group of 
neurons, we performed post-hoc immunohistochemical staining with different cellular markers of 
the recorded neurons to delimit the cellular identity of RSNPCs. The morphological properties of 
these cells (lack of apical dendrite) led to the suggestion that these cells are interneurons. To prove 
this hypothesis we stained the slices for glutamic acid decarboxylase (GAD) 67, an enzyme that 
catalyzes the decarboxylation of glutamate to GABA and can be used as an interneuron marker 
(Figure 28A). 63 cells determined as RSNPCs were stained for GAD67, of which 31 cells showed a 
positive staining (49%). It is not clear whether the GAD67-negative cells did not express this 
interneuron marker, or if it was washed out from the cytosol during the whole-cell recording. In a 
subset of RSNPCs that were subsequently stained for GAD67, AP trains (Figure 28C) of HU-308 
applications (Table 5) was used to elicit SSI. Amplitude and incidence of SSI were indistinguishable 
between GAD67-positive and GAD67-negative cells (Figure 28C; Table 5) indicating a physiological 
homology between these groups, independent of the detectability of GAD67 expression. 
 
 
Figure 28: RSNPCs express the cellular markers GAD67 and Reelin.  
A - B: Post-hoc immunohistochemical analysis of the recorded cells (green: Biocytin) identified as 
RSNPCs revealed that a subset of these cells express the cellular markers GAD67 (A) and Reelin (B). 
Scale bar: 20 µm. C: Trains of APs induced SSI to a similar extend in RSNPCs that were positive (+) or 





Cortical interneurons can be divided in three major groups: parvalbumin, somatostatin and serotonin 
receptor type 3A (5HT3A)-expressing interneurons (Rudy et al., 2011). We have found that FSs 
(putative parvalbumin-expressing) and putative somatostatin-expressing interneurons show a 
different firing pattern compared to RSNPCs, indicating that the latter cell type is rather part of the 
5HT3A subgroup of interneurons. This group can be subdivided in vasoactive intestinal peptide (VIP)-
expressing and non-VIP-expressing interneurons, while 80% of the latter group express the cellular 
marker Reelin (Rudy et al., 2011). 57 cells that were distinguished as RSNPCs were stained for Reelin 
(Figure 28B) and 18 cells showed a positive staining (31%). In 22 RSNPCs that were subsequently 
stained for Reelin, AP trains were applied to elicit SSI and both groups showed pronounced SSI 
expression (Figure 28C; Table 5).  
In conclusion, we show that at least a subset of RSNPCs express GAD67 or Reelin indicating that 
RSNPCs are putatively part of the 5HT3A-expressing subgroup of interneurons. 
 
Table 5: Parameters of SSI in RSNPCs that were post-hoc immunohistochemically stained for cell 
markers. 
 Nr. of experiments Average Vm (mV) Responding cells 
GAD67-positive (APs) 15 -4.3 ± 0.9 11/15 
GAD67-negative (APs) 15 -4.9 ± 0.9 11/15 
Reelin-positive (APs) 9 -5.4 ± 1.1 8/9 





-6.1 ± 3.0 
-4.0 ± 1.7 
3/4 
3/5 
SSI induction protocol is indicated in brackets; Average Vm values are given as mean ± SEM including 




4.1 Hippocampal SSI 
4.1.1 Mechanism of hippocampal SSI 
Upon the discovery of SSI in the hippocampus, it was shown that the long-lasting hyperpolarization 
was not accompanied with a change in input resistance (Stempel et al., 2016) arguing against the 
involvement of a conductance-based mechanism like gating of ion channels. Thus, we considered ion 
pumps or transporters to mediate the hyperpolarization since pump or transporter activation can 
lead to hyperpolarization without affecting the membrane conductance. To identify the underlying 
mechanisms, we performed experiments in which we altered different components involved in the 
energy metabolism of the cell; however, we were still able to elicit the long-lasting hyperpolarization 
suggesting the involvement of an ATP-independent ion transporter (Figure 9A). By systematically 
substituting several ions form the intra- and extracellular solution we identified Na+ as necessary ion 
for SSI induction (Figure 9B, C). It was previously shown that cannabinoid receptors can modulate the 
activity of the Na+/H+ exchanger (Bouaboula et al., 1999), thus we pharmacologically blocked several 
transporters to determine their involvement in hippocampal SSI (Figure 9E, F). Finally, we could 
identify a specific antagonist of the electrogenic Na+/bicarbonate cotransporter (NBC) that blocked 
both AP- and agonist-induced long-lasting hyperpolarization (Figure 10), suggesting the NBC as 
downstream target of CB2Rs in hippocampal PCs. 
However, the molecular transduction pathway underlying CB2R-mediated activation of the NBC is not 
clear. An IP3 receptor-binding protein (IRBIT) was shown to specifically bind and activate NBC 
(Shirakabe et al., 2006). At low IP3 concentrations IRBIT binds to IP3 receptors at the ER, inhibiting 
their action and acting as a gatekeeper (Ando et al., 2003). It was demonstrated that NBC activity is 
stimulated by PIP2 and IP3 (Thornell and Bevensee, 2015; Thornell et al., 2012). Thus, increased IP3 
production via PLC activation leads to its binding to IP3-receptors releasing IRBIT and inducing Ca
2+ 
efflux from the ER. Cannabinoids can elicit intracellular Ca2+ transients via activation of CB1Rs (Sugiura 
et al., 1997) or CB2Rs (Zoratti et al., 2003) by increasing PLC activity (Hillard and Auchampach, 1994) 
in a Gi/o-dependent manner (Lograno and Romano, 2004). A speculative transduction mechanism 
could be therefore that upon CB2R activation, Gi/o or the Gq activate PLC, which metabolizes PIP2 
to DAG and IP3. Subsequently, IP3 binds to ER-bound IP3 receptors and releases IRBIT, which then 




Figure 29: Possible model for NBC activation downstream of agonist binding to CB2R.  
A: Resting state. B: Agonist binding to CB2R increases PLC activity and intracellular IP3 concentration 
via Gi/o. IP3 binds to IP3R and releases IRBIT that in turn binds to NBC and enhances its activity. 
Further, IP3R opening leads to Ca
2+ influx from the ER, activating calcineurin that stimulates NBC 
activity. Modified from Ando and Mikoshiba 2014. 
 
In addition, we performed a series of experiments with intracellular application of the Ca2+ chalator 
BAPTA and saw that not only the AP-induced SSI was abolished, but also agonist-induced long-lasting 
hyperpolarization was prevented (Figure 11). This hints towards a Ca2+-dependent mechanism 
downstream of CB2R activation mediating activation of the NBC. Although, it is not clear how CB2R 
activation and Ca2+ signaling might be connected in this process, it is possible that the Ca2+ influx 
from intracellular stores via IP3Rs might be crucial for either direct activation of NBCs or for 
exocytosis of additional NBCs to increase surface expression (Ando et al., 2014). Calcineurin, a Ca2+-
dependent protein phosphatase, was shown to interact with NBCs to stimulate its activity upon raise 
in intracellular Ca2+ (Danielsen et al. 2013). This stimulation was inhibited by BAPTA supporting our 
finding of Ca2+ dependency for NBC activation (Danielsen et al. 2013). In addition, PLC activity was 
shown to be regulated by both, intracellular Ca2+ concentration as well as GPCR-activation. Thus, the 
hypothesized coupling mechanism of CB2Rs with NBC, might be regulated by intracellular Ca
2+ and 
PLC could act as a coincidence-detector for CB2R activation and neuronal activity. Future studies have 
to address the molecular transduction pathway of SSI downstream of CB2R activation in more detail. 
Ca2+ imaging experiments could help to understand the role of alteration in intracellular Ca2+ 
concentration after CB2R activation and could show whether certain cell organelles such as the ER or 
mitochondria take part in this process. 
Activation of NBC changes intra- and extracellular pH values that can alter neuronal activity. 
Generally, increase in extracellular pH stimulates neuronal activity, while reduced pH decreases it 
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(Sinning and Hübner, 2013). This arises from the pH-sensitivity of several metabolic enzymes and ion 
channels. Neuronal activity is thought to cause a transient extracellular alkalosis, thus excessive 
neuronal firing leads to an initial extracellular alkalization followed by a more prolonged acidification. 
Electrogenic NBCs are expressed in CA3 PCs, are upregulated during extracellular acidosis (Oehlke et 
al., 2013) and couple changes in pH with neuronal activity (Majumdar et al., 2008). Vice versa, 
activation of NBCs may affect neuronal excitability by influencing local pH (Chesler, 2003). 
Intracellular pH of neurons was shown to be linked to depolarizing stimuli: Ca2+ entry leads to a fall in 
intracellular pH due to Ca2+/H+ exchange by Ca2+-ATPases located in the plasmamembrane and ER 
(SERCA; Chesler, 2003). In response to low cytosolic pH, neurons can either actively extrude H+ from 
the cytosol or import bicarbonate into the cells via NBC, a mechanism termed depolarization-induced 
alkalinization (DIA). This effect is present in astrocytes and in hippocampal neurons (Svichar et al., 
2011) and is thought to represent a mechanism to preempt a large, prolonged, Ca2+-dependent 
acidosis. However, it is not clear by which mechanism NBCs get activated in DIA. 
In hippocampal PCs, it is unclear whether the Na+ transport or the pH change is the more important 
component for the hyperpolarization and establishment of SSI. The Na+ gradient might act as the 
energy source for the transport of bicarbonate resulting in deacidification of the intracellular space. 
Despite having different time-courses, the induction protocols for both SSI and DIA share several 
characteristics including membrane depolarization and Ca2+-dependency (Figure 11; Svichar et al., 
2011), speculatively suggesting similar mechanisms involved. Thus, activation of NBC during SSI not 
only hyperpolarizes the cell, but may also lead to deacidification of the cell and a decrease in 
extracellular pH. Since these effects converge to decrease neuronal activity, it is conceivable that 
hippocampal SSI may represent a cell-protective effect to prevent cell damage due to over-
excitability. In addition, it is possible that cell-autonomous CB2R activation might represent the 
cellular mechanism for DIA in which excessive Ca2+ influx leads to activation of NBCs. Future studies 
have to analyze if SSI induction alters the extra- and intracellular pH, whether SSI may be occluded by 
acute manipulation of the pH of the extracellular solution and by which terms SSI and DIA are 
mechanistically connected. 
In summary, excessive activity in hippocampal PCs leads to a strong Ca2+ influx into the cell that 
stimulates 2-AG production. 2-AG activates cell-autonomously CB2Rs, resulting in SSI. On a 
speculative note, simultaneous CB2R activation and prolonged elevated Ca
2+ may stimulate PLC, 
which activaties NBC in an IP3- and IRBIT-dependent manner (Figure 29). For the neuronal physiology, 
this might represent a protective mechanism that reduces excitability by hyperpolarization and 
prevents damages by Ca2+-induced acidosis via DIA.  
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4.1.2 Cell type-specific expression of SSI 
We demonstrated that brief trains of APs induce SSI in hippocampal CA3 and CA2 PCs, but not in CA1 
PCs, dentate gyrus granule cells (Stempel et al., 2016), nor OLM cells (Figure 12). Surprisingly, direct 
activation of CB2Rs by the specific inverse agonist HU-308 induced a long-lasting hyperpolarization in 
a similar occurrence and amplitude in CA1 PCs as in CA3 PCs. This effect was abolished with NMDG-
ACSF as well as in presence of the NBC blocker S0859. Thus, CA1 PCs seem to express functional 
CB2Rs that are probably coupled through the same molecular mechanism to NBC. Further evidences 
for the expression of functional CB2R in CA1 PCs exists: CB2R mRNA was detected in CA1 PCs (Stempel 
et al., 2016) and deletion of CB2Rs was shown to reduce synaptic transmission and LTP in CA1 (Li and 
Kim, 2016). Further, cell type-specific deletion or overexpression of CB2Rs in CA1 PCs enhanced 
spatial working memory or reduced anxiety levels, respectively (Li and Kim, 2017). Several studies 
demonstrated that CA1 PCs are capable to produce and release endocannabinoids in different 
physiological conditions including DSI (Wilson and Nicoll, 2001), DSE (Ohno-Shosaku et al., 2002b) 
and LTD (Chaveleyre and Castillo, 2003). However, CB2Rs on CA1 PCs could not be activated by AP 
trains, even with increased stimulation intensities (Stempel et al., 2016), hinting towards an 
induction failure of SSI. It is possible that the cellular location of endocannabinoid production and 
CB2Rs are different in CA1 and CA3 PCs hindering cell-autonomous CB2R activation in CA1 PCs under 
physiological conditions. The presence of SSI in CA3 PCs might highlight its relevance as a cell 
protective mechanism in CA3, since CA3 PCs form recurrent connections that enhance network 
excitation, rendering them sensitive to hyperexcitability-induced damage (Guzman et al., 2016). A 
recent study demonstrated in a model of pilocarpine-induced epilepsy that after status epilepticus 
the number of neurons decreased in CA3 and CA1 due to increased apoptosis, while the number of 
CB2R-positive cells as well as the CB2R expression increased (Wu and Wang, 2018), supporting the 
hypothesis of a neuroprotective mechanism. It is conceivable that under physiological conditions 
some unknown factors impede SSI induction in CA1 PCs although these cells express functional CB2Rs 
(Stempel et al., 2016). Under pathological conditions, however, these unknown factors might change 
and SSI induction could be facilitated. Future studies investigating SSI under hyperexcitable 
conditions will probably elucidate the conditions for successful SSI inductionin CA1 to deepen our 
understanding of the physiological relevance of this effect under different conditions and in different 
cell types. 
Our data show that OLM interneurons do not express SSI and direct activation of CB2Rs does not 
hyperpolarize the cells (Figure 12). It is unclear whether this cell type expresses CB2Rs or the NBC. In 
general, SSI is not restricted to excitatory cells since another type of interneuron in the 
somatosensory cortex was shown to express SSI: Trains of APs induce a long-lasting hyperpolarization 
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in layer 5 LTS interneurons (Bacci et al., 2004; Marinelli et al., 2008). However, it would be interesting 
to study additional hippocampal interneuron cell types to determine the presence of SSI in inhibitory 
cells in the hippocampus. It remains unclear why only distinct cell types express SSI. 
 
4.2 Cortical SSI 
4.2.1 Responding and non-responding cells 
SSI is expressed in a cell type-specific manner, and most studies find that only a fraction of cells from 
one cell type express SSI (Figure 14; Bacci et al., 2004; Marinelli et al., 2009; Stempel et al., 2016). In 
light of the existing literature and our data, it is possible to identify potential explanations for this: 
We showed that trains of AP induce SSI in RSNPCs and PCs in layer 2/3 of the somatosensory cortex 
but not in FSs (Figure 14). This cell type-specific expression of SSI was also described for layer 5 of the 
somatosensory cortex, where only LTS interneurons, but not FS neurons exhibited SSI (Bacci et al., 
2004). It was suggested, that SSI represents a form of self-inhibition to alter intrinsic excitability of 
LTS neurons as an alternative mechanism to autaptic synapses that were found on FSs (Bacci et al., 
2003, 2004). For excitatory cortical networks SSI might represent a self-regulatory dampening 
mechanism (Marinelli et al., 2009). 
In cortex layer 2/3 PC Marinelli et al. were able to elicit SSI in 26% of PCs with average 
hyperpolarization amplitude of 4.75 mV (Marinelli et al., 2009), while in our recordings 
approximately 70% of the PCs were responding to the AP trains with average amplitude of 5.9 mV 
(Figure 13). This increased prevalence might be explained by the use of different intracellular 
solutions: While Marinelli et al. were using K-gluconate-based intracellular solution our solution was 
K-Methylsulfate-based. In our previous study we demonstrated that it was not possible to induce SSI 
in hippocampal PC with K-gluconate based intracellular solution (Stempel et al., 2016). This 
induction-failure can be explained by the Ca2+ buffering effects of gluconate (Woehler et al., 2014). 
We showed that a BAPTA-containing intracellular solution blocked both, AP-induced as well as 
agonist-induced long-lasting hyperpolarization in hippocampal PC (Figure 11). Thus, gluconate in the 
patch pipette could prevent or reduce either the Ca2+-dependent production of endocannabinoids or 
the Ca2+-dependent down-stream mechanism after CB2R activation.  
However, we also found a fraction of cells not responding to the induction stimuli (AP trains or 
agonist application) when recorded in whole-cell configuration, although they belonged to cell types 
generally capable of SSI expression (Figure 14; Figure 15; Stempel et al., 2016). The AP trains for SSI 
inductions were similar in amplitude and no substantial decline could be observed in responding and 
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non-responding cells (Figure 17). Further, we showed that responding and non-responding cells (for 
both RSNPCs and PCs) had similar electrophysiological properties (Figure 16). However, we noticed 
that the AP half width was significantly higher in responding RSNPCs compared to the non-
responding cells. This trend was also observed in PCs although the difference was not statistically 
significant (Figure 16). The shorter AP durations could cause less Ca2+ to enter the cell, thus it may be 
insufficient to trigger endocannabinoid production. On the other hand, the percentage of responding 
to non-responding cells was similar when the long-lasting hyperpolarization was induced by CB2R 
agonist application, arguing against an induction failure of SSI due to reduced Ca2+ entry. Moreover, 
in our previous study (Stempel et al., 2016) we showed that SSI was present in all pyramidal cells 
when recorded in perforated patch configuration, which renders the intracellular milieu intact. This 
argues in favor of non-biological, experimental factors being responsible for ‘successful’ SSI 
induction. To summarize, we think that unsuccessful SSI induction depends on the recording 
conditions rather than on biological differences regarding firing properties of cells. 
It was previously suggested that the responsiveness of PCs to SSI induction depends on the PC 
subtype (Marinelli et al., 2009): Dendrites of responding cells were found more branched but less 
extended towards the superficial layers compared to dendrites of non-responding cells. Further, 
repeated AP trains decreased the amplitude of evoked IPSCs more reliable in responding cells then in 
non-responding cells. DSI could be evoked less frequently in non-responding cells (Marinelli et al., 
2009), arguing for a biological heterogeneity of PCs regarding their cannabinoid signaling. 
Remarkably, RSNPCs are not able to induce DSI, despite receiving CB1R sensitive inhibitory input, 
which led to the suggestion that endocannabinoid production in RSNPCs is impaired (Lemtiri-Chlieh 
and Levine, 2007). However, we demonstrate that RSNPCs are capable of producing sufficient 
endocannabinoids for successful SSI induction. In addition, we showed that under our recording 
conditions, it is sufficient to apply the induction protocol once (10 trains of 50 APs) to induce SSI 
(Figure 19A), and that SSI cannot be further potentiated (Figure 19B, C; Figure 23).  
It is conceivable that the recording conditions used in Marinelli et al. (whole-cell recordings, K-
gluconate intracellular solution) lead to the high occurrence of non-responding cells (Marinelli et al., 
2009) due to wash-out or Ca2+ buffering resulting in impairment of endocannabinoid production. All 
this could lead to the impression of a biological heterogeneity in PCs, which could have been 
misinterpreted in regard to cannabinoid signaling. In order to unequivocally identify the true nature 
of the occurrence of SSI and other cannabinoid mediated effects in cortical PCs, future studies using 




4.2.2 CB2Rs are mediating SSI 
We investigated the underlying mechanism of SSI in detail using pharmacological tools (Figure 22; 
Figure 23) as well as CB1R- and CB2R-deficient mice (Figure 25; Figure 26). We found that SSI is 
selectively mediated by CB2Rs in both RSNPCs as well as PCs. This is somewhat unexpected as CB1Rs 
were previously implicated in SSI of PCs in layer 2/3 of somatosensory cortex (Marinelli et al., 2009). 
It is conceivable that the finding of CB1R-dependency in SSI arose due to several factors: Marinelli et 
al. used the CB1R inverse agonist AM-251 in a concentration (3 µM) that also inhibits CB2Rs (Stempel 
et al., 2016). Thus, the abolishment of SSI in the presence of AM-251 does not prove the involvement 
of CB1Rs in this effect. Further, it was shown that SSI incidence was reduced in CB1R KO mice 
(Marinelli et al., 2009). However, since only 26% of the PCs in WT mice could induce SSI, and 
approximately 8% of the tested PCs in the CB1R deficient mice were still able to express SSI (Marinelli 
et al., 2009), the involvement of CB2Rs cannot be excluded.  
Our data show that in cortical regular spiking neurons SSI is mediated via activation of CB2Rs. 
Application of the selective CB2Rs agonist triggers a long-lasting hyperpolarization, while 
pharmacological activation of CB1Rs does not change the membrane potential (Figure 22). Additional 
experiments showed that SSI and agonist-induced CB2R activation occlude each other suggesting a 
shared intracellular transduction pathway (Figure 23). In line with this finding, preincubation with a 
CB2R specific inverse agonist prevented induction of SSI. However, the CB1R inverse agonist Ly320135 
also decreased the amplitude of SSI, while the occurrence of responding cells was comparable to 
control conditions (Figure 24). The reported Ki values for Ly320135 at CB2Rs determined in cell 
culture assays and binding studies is much higher (>10 µM; Felder et al., 1998) as the used 
concentration (1 µM) argueing against a direct interaction with CB2Rs. However, it is still possible 
that application of this compound might affect CB2R activity: One possible explanation is the 
presence of CB1R/CB2R heterodimers which were found to be expressed and functional in several 
brain regions (Callen et al., 2012; Sierra et al., 2015). Since these heterodimers show bidirectional 
cross-antagonism, it is conceivable that the CB1R-selective inverse agonists might affect CB2Rs due to 
direct interaction in CB1R/CB2R heterodimers. Despite the uncertainty of the functional relevance of 
these heterodimers, experimental data indicate a crosstalk between different effects mediated by 
both cannabinoid receptors. In addition, cells expressing both receptor types were shown to exhibit 
reduced biased agonism, suggesting that heterodimers reduce functional selectivity of agonists 
(Navarro et al., 2018).  
Several recent studies have described the role of CB2Rs in neuronal self-inhibition: In hippocampal 
pyramidal neurons CB2Rs mediate SSI after trains of APs (Stempel et al., 2016). Intracellular CB2Rs 
reduce firing frequency in PCs of the prefrontal cortex (den Boon et al., 2012). Furthermore, 
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application of CB2R agonists hyperpolarizes dopaminergic neurons of the ventral tegmental area and 
inhibits spiking due to activation of M-type K+ channels (Ma et al., 2019; Zhang et al., 2014). Together 
these findings illustrate that CB2R activation can modify excitability in several different cell types and 
brain regions. Our work demonstrates an additional CB2R-mediated mechanism for cell-autonomous 
self-inhibition. Further determination of the inhibitory properties of CB2R activation would help us 
understand whether this effect represents a brain wide phenomenon or if it is restricted to specific 
brain regions.  
 
4.2.3 Mechanism of cortical SSI 
CB1R-mediated GIRK channel activation was described as the mechanism responsible for SSI in layer 
2/3 PCs and layer 5 LTS interneurons (Bacci et al., 2004; Marinelli et al., 2009). In the present study, 
we demonstrate that hippocampal and cortical SSI show different transduction pathways. Despite 
sharing the foregoing CB2R activation, hippocampal SSI is established by the activation of NBC (Figure 
10) while cortical SSI is based on GIRK activation (Figure 20; Figure 21). GIRK activation by CB2Rs most 
likely occurs via direct activation by the G subunit (Guo and Ikeda, 2003), while the activation of 
NBC is not yet worked out, but may occur in the above suggested pathway (chapter 4.1; Figure 29).  
Given the variability of intracellular transduction protein expression across different classes of 
neurons, it is not surprising that multiple mechanisms and downstream signaling cascades are 
involved in a phenomenon such as SSI (Arey, 2014). Several studies have shown that CB2Rs activation 
can lead to selective utilization of different transduction pathways (Atwood et al., 2012a; 
Dhopeshwarkar and Mackie, 2016). Thus, cell type-specific variations of the intracellular signaling 
machinery may determine which transduction pathway is implemented after agonist binding. The 
recruitment of different intracellular pathways in hippocampal and cortical neurons by CB2Rs could 
be explained by the presence of CB1R/CB2R heterodimers expressed in these cell types, leading to 
altered conformational properties of CB2Rs resulting in different coupling to intracellular cascades by 
favoring of one G protein over another (chapter 1.2.1.3). Different expression of intracellular binding 
proteins was also shown to influence the confirmation of GPCRs resulting in biased recruitment of 
intracellular pathways (DeVree et al., 2016). For example, activation of the GPCR M3 muscarinic 
receptor mediates very specialized tissue-specific responses upon activation in different cell types: 
while it regulates membrane excitability in neurons, it mediates contraction and cell growth in 
smooth muscle cells (Torrecilla et al., 2007). It was shown that M3 muscarinic receptors can be 
differently phosphorylated in different cell types due to expression of different protein kinases 
resulting in recruitment of different signaling pathways (Torrecilla et al., 2007). Thus intracellular 
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properties and expression profiles (location and expression levels) of CB2Rs, their corresponding 
binding partners and specific protein kinases might lead to cell type-specific coupling to different 
transduction pathways. It is conceivable that this leads to the recruitment of G signaling in cortical 
neurons that directly activates GIRK channels, while hippocampal SSI is mediated via Gq proteins to 
activate NBC. The exact molecular transduction pathways still have to be identified for both cortical 
and hippocampal SSI in the different cell types. 
The possibility of utilizing different transduction pathways upon agonist binding and the presence of 
biased agonism on CB2Rs might represent a promising strategy to use CB2Rs as therapeutic targets 
for several pathological conditions (chapter 1.2.3). Thus, the development of specific CB2R agonists, 
which favor one beneficial intracellular pathway over another, might improve the therapeutic effects 
while reducing possible side effects. However, for CB2Rs it is still unclear which intracellular pathways 
will elicit the most benefitial effects in which cell type and brain region to treat pathological 
conditions. 
 
4.2.4 Physiological relevance  
4.2.4.1 Activation pattern 
In terms of the physiological relevance of the phenomenon under study, it has been shown before 
that SSI can be induced with more naturally spaced activity patterns than the induction patterns used 
in this study: physiological spike trains from in vivo recordings were applied in slices and induced SSI 
in CA3 pyramidal neurons of similar magnitude as the regular-spaced AP trains (Stempel et al., 2016). 
Similarly, Marinelli et al. could reliably induce SSI in cortical PCs with spike trains of lower (10-50 Hz) 
frequencies (Marinelli et al., 2009). In this context it is noteworthy that for somatosensory cortex 
layer 2/3 regular spiking pyramidal neurons, firing frequencies of up to 60 Hz have been reported 
(Kinnischtzke et al., 2012). Therefore, SSI can be induced by activity patterns of neurons that occur in 
vivo. In this study, we purposefully used an induction protocol of slightly higher activity levels with 
aiming at a robust SSI amenable to pharmacological dissection of the mechanism. However, the 
specific role of SSI under physiological conditions has to be addressed experimentally in more detail. 
 
4.2.4.2 Network effects 
Although all layers of the somatosensory cortex receive sensory information from the thalamus, the 
highest density of thalamocortical axons can be found in cortical layer 4, which is regarded as the 
major input layer. From layer 4, the incoming thalamocortical excitation spreads most prominently to 
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layer 2/3 PCs, which connect locally to neighboring L2/3 PCs as well as vertically to layer 5 cells and 
horizontally to different cortical columns to layers 2/3 and 5 (Feldmeyer, 2012). The main outputs of 
the somatosensory cortex are projections from PCs in layer 5. Excessive neuronal activity, due to 
strong sensory stimulation or due to pathological conditions, might induce SSI in PCs of layer 2/3 
resulting in an inhibition on a cellular level preventing hyperexcitability of the cell (Figure 30). Next to 
the hyperpolarization, decrease of the cellular input resistance supports the inhibitory effects during 
SSI. Thus, on the network level, SSI induction in PCs might affect the inter- and intralaminar spread of 
excitation to the following cells. 
Next to this classic excitatory circuitry, layer 2/3 interneurons receive inputs from excitatory cells of 
layer 2/3 as well as from layer 4 (Helmstaedter et al., 2008). In line with our observation, RSNPCs 
were described as the most common type of interneuron in layer 2/3 of the somatosensory cortex 
(Lemtiri-Chlieh and Levine, 2007). Cortical interneurons can be divided into three: somatostatin-, 
parvalbumin- and 5-HT3A-expressing interneurons (Rudy et al., 2011). Due to the characteristic firing 
pattern (Figure 13; Table 4), the FSs recorded in this study represent most likely parvalbumin-
expressing interneurons. We also showed that putative somatostatin-expressing neurons show a 
different firing pattern compared to RSNPCs and do not express SSI (Figure 18). 
Immunohistochemical analysis showed that a subset of RSNPCs expressed the interneuron marker 
GAD67 and cellular marker Reelin (Figure 28). Since whole-cell recordings lead to washout of cellular 
markers that cannot be stained after recordings (Marinelli et al., 2008), it is conceivable that the 
percentage of the positively stained cells do not represent the physiological distribution of the cell 
markers in RSNPCs. 
It is likely that RSNPCs belong to the subgroup of 5HT3A-expressing interneurons, which preferentially 
synapse onto other interneurons, preferably somatostatin-expressing interneurons (Tremblay et al., 
2016). This interneuron class can be subdivided in VIP-expressing and non-VIP-expressing 
interneurons, while 80% of non-VIP-expressing neurons express Reelin, and are mainly but not 
exclusively located in layer I of the somatosensory cortex. Further, 60% of VIP-expressing 
interneurons are located in layer 2/3 and represent the most prominent interneurons class in this 
layer (Rudy et al., 2011). Since our experiments were conducted in layer 2/3, most of the recorded 




Figure 30: Simplified scheme of cortical circuit demonstrating putative role of SSI on information 
processing.  
A: Somatostatin (SST)-expressing cells connect to dendritic regions of PCs and parvalbumin (PV)-
expressing interneurons (putative FSs). PV interneurons connect to each other and to somatic 
regions of PCs, while VIP interneurons (putative RSNPCs) connect most prominently to SST 
interneurons. (+): excitatory connection; (-): inhibitory connection B: Excessive excitatory input (red 
fibers; depicted by increased (+) sign) induces SSI in VIP and in PCs leading to their inhibition 
(decreased excitability depicted by green arrow). Inhibition of VIP neurons renders disinhibition of 
SST-interneurons supporting the inhibition of PCs. Together SSI in both cell types might reduce or 
even shunt information transmission from the PC to following structures. Modified from Deleuze et 
al., 2014. 
 
In vitro analysis of the interaction scheme of the three main interneuron populations and principal 
cells in the visual cortex revealed that VIP-expressing interneurons establish fewer synaptic contacts 
to PCs with low synaptic strength compared to the other interneuron types. However, VIP-expressing 
cells primarily target other interneurons: most prominently somatostatin-expressing cells (Pfeffer et 
al., 2013). The inhibition of somatostatin-expressing neurons by VIP was shown to be fundamental 
for motor integration in the somatosensory cortex (Lee et al., 2013) as well as for information 
processing in the medial prefrontal cortex and the auditory cortex (Pi et al., 2013). The net effect of 
VIP-positive neuron recruitment is a disinhibition of PCs, resulting in increased firing of principal 
neurons (Pi et al., 2013). Conversely, it is likely that inhibition of VIP-positive neurons by SSI leads to 
decrease in PC firing. Excessive excitatory signaling may converge onto layer 2/3 RSNPCs, eliciting SSI 
resulting in a disinhibition of other interneurons, effectively adding to the excitation protection of 
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PCs (Figure 30B). Additionally, if the input fibers target also somatostatin- and parvalbumin-
expressing interneurons (Isaacson and Scanziani, 2011), elevated excitatory input would increase 
feedforward inhibition and support the inhibition of PCs induced by SSI in RSNPCs and PCs. Since 
parvalbumin-expressing interneurons and putative somatostatin-expressing interneurons do not 
express SSI (Figure 13; Figure 18) this feedforward inhibition would not be attenuated by this cell-
intrinsic mechanism. 
The long-term stability of SSI after induction (Figure 19A) is a further indication that it might occur in 
specific events when excessive activity must be prevented for a longer period of time. The finding 
that SSI cannot be repetitively induced (Figure 19B, D) supports its association as an intrinsic safety-
switch to prevent cellular damage arising from excitotoxicity. 
In summary, the presence of SSI in both, RSNPCs as well as PC of layer 2/3 in the somatosensory 
cortex might present an activity-dependent safety mechanism preventing the spread of over-
excitability to adjacent brain regions by reducing both cellular and network excitability. By inducing 
SSI, PCs hyperpolarize which renders the cell less excitable and prevents the propagation of 
excitatation. SSI in RSNPCs might support the inhibition of PCs by disinhibition of interneurons that 
target PCs (Figure 30). Further experiments should be performed in which whole-cell patch clamp 
recordings of PCs in layer 2/3 determine the effect of CB2R agonist application on the incoming 
inhibitory currents: Does global CB2R activation types lead to increased inhibition on PCs? In addition, 
extracellular stimulation of excitatory inputs on PCs should be performed to determine if CB2R 
activation reduces spike probability in cortical PCs, giving insight in the role of SSI in information 
transmission for the network. 
It was hypothesized that LTS-interneurons of layer 5 might express SSI to control the flow of sensory 
information to the PC in layer 5, since LTS neurons target the dendrites of the latter. Thus, induction 
of SSI in LTS interneurons would result in disinhibition of layer 5 PCs to increase excitation (Bacci et 
al., 2004), in contrast to decreased excitation in layer 2/3 PCs showed in this study.  
Neuronal CB2Rs modulate oscillatory activity – more specific theta-gamma-coupling in the 
hippocampal formation (Stempel et al., 2016). Interestingly, it was shown that gamma oscillations in 
human primary somatosensory cortex reflect pain perception (Gross et al., 2007; Zhang et al., 2012) 
and sensory gating (Cheng et al., 2016). The primary somatosensory cortex is seen “as a site for 
integration of input from different afferent sources leading to perceptual recognition of the 
presence, location, intensity, submodality and quality of touch and pain” (Vierck et al., 2013). It was 
shown in an animal model for central pain syndrome that neurons in the somatosensory cortex 
exhibited higher spontaneous activity as well increased responses evoked by innocuous and noxious 
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stimuli (Quiton et al., 2010). Given the fact that SSI is more prominent in occurrence as well as in 
amplitude in PC in somatosensory cortex compared to CA3, it is conceivable that activation of CB2Rs 
might also modulate oscillatory activity in this brain area. In addition, the expression of SSI in both, 
PCs as well as in RSNPCs might suggest an even stronger significance for network modulation. Thus, 
activation of CB2Rs might possibly be a way to decrease cortical excitation having beneficial effects 
on pain sensation in central pain syndrome. 
In conclusion, it is important for future research to identify the precise cellular identity of RSNPCs by 
using specific interneuron reporter lines (Reelin-Cre x Ai9, VIP-Cre x Ai9 or 5HT3A-BAC-GFP) as well as 
more detailed immunohistochemical stainings to understand the role of SSI in the specific cell types. 
Further, it will be interesting to see the effects of SSI on the network level: How does CB2R activation 
affect the transmission and processing of the information in layer 2/3? Do the network effects 
induced by SSI differ between layer 2/3 and layer 5 of the somatosensory cortex? Are neuronal 
oscillations such as up-down states affected?  
 
4.3 Neuroprotective role of CB2Rs 
Due to the low CB2R expression levels in neuronal cells under physiological conditions, it has been a 
challenging task to study CNS effects of CB2Rs. Unspecific CB1R-pharmacology (Stempel et al., 2016) 
and CB2R antibodies of insufficient specificity (Cecyre et al., 2014; Marchalant et al., 2014; Zhang et 
al., 2019) have previously impeded a convincing discrimination between CB1R- and CB2R-mediated 
effects in the CNS. However, in recent years, evidence accumulated suggesting that both CB1- and 
CB2Rs serve divergent physiological effects. Stempel et al. and Chen et al. proposed that CB1Rs seem 
to be mainly involved in modulation of synaptic functions while CB2R activation results in 
postsynaptic inhibition (Chen et al., 2017; Stempel et al., 2016). A plethora of studies showed the 
involvement of microglial and neuronal CB2Rs in various pathological conditions (chapter 1.2.3). For 
example, manipulation of CB2R expression in CA1 PC or microglia was shown to induce distinct 
behavioral phenotypes in mice: while microglial CB2Rs were involved in contextual fear memory, 
overexpression or disruption of CB2Rs in PC lowered anxiety levels or enhanced spatial working 
memory, respectively (Li and Kim, 2017). Moreover, constitutive deletion of CB2Rs induces a 
schizophrenic phenotype in mice (Ortega-Alvaro et al., 2011), increases aggressive behavior 
(Rodriguez-Arias et al., 2015) and modulates drug-seeking behavior for ethanol (Ortega-Alvaro et al., 
2015) and nicotine (Navarrete et al., 2013). CB2R expression was also increased after status 




In line with the protective role assigned to CB2R signaling (Pacher and Mechoulam, 2011), the CB2R 
mediated self-inhibition described here may represent a cell-autonomous feedback loop preventing 
neurons from damage due to excessive excitability. SSI-induced hyperpolarization is indiscriminately 
observed in different types of regular spiking cells (cortical PCs, RSNPCs, CA3 PCs). In contrast, FSs do 
not show this phenomenon, which argues in favor of a protective role against intolerable amounts of 
excitation. It is well-known that different cell types show different properties in Ca2+ buffering 
(Matthews and Dietrich, 2015). Thus it is conceivable that some cell types are more sensitive to 
excessive intracellular Ca2+ increase due to the absence of fast and effective buffering mechanisms. 
Depending on the excitatory inputs under physiological conditions, some cell types may require 
mechanisms to prevent over-excitability due to Ca2+ influx. For example, FSs express the Ca2+ buffer 
parvalbumin that is not present in regular spiking neurons, possibly rendering these cells more 
tolerable to excitability. In addition, we showed that SSI induction is sensitive to intracellular Ca2+ 
handling, since both BAPTA and K-gluconate based intracellular solution interfered with the induction 
of SSI (Figure 11; Stempel et al., 2016). One possibility is that introducing additional Ca2+ buffering 
mechanisms to the cells (intrecellular BAPTA or gluconate) results in an increased Ca2+ tolerance of 
the recorded cell. Hence, the threshold for activation of a potential protection mechanism, to 
support the cell coping with elevated intracellular Ca2+ would be increased and thus SSI induction 
prevented. In addition, the different AP half widths in responding and non-responding RSNPCs might 
argue in favor of the involvement of Ca2+ handling for SSI induction, since larger AP half widths lead 
to increased Ca2+ entry into the cell.  
Interestingly, SSI is present in both, hippocampal and cortical neurons, suggesting a general role for 
CB2R-mediated self-inhibition. Trains of APs induce a long-lasting hyperpolarization in regular spiking 
cells in both regions (Figure 7; Figure 13). However, the underlying mechanism of SSI differs between 
hippocampus and the somatosensory cortex: while hippocampal SSI represents an input resistance-
independent mechanism which is established via activation of NBCs (Figure 10), cortical SSI is 
accompanied with a change in input resistance due to GIRK activation (Figure 20). Next to the 
decrease in cell-excitability through hyperpolarization, both mechanisms can further support the 
inhibitory manner of SSI: Change of extracellular pH might suppress excessive excitation without 
preventing information transmission, while GIRK activation could lead to shunting of the incoming 
excitation and thus result in a separation of the cell from the network. On a speculative note, SSI that 
reduces the input resistance might be more effective as a protective mechanism: It can change the 
dendritic integration and can lead to the exclusion of a cortical cell from the network in episodes of 
excessive excitation to prevent cellular damage. On the other hand, changes in extracellular pH by 
NBC might serve as a modulatory mechanism to inhibit excessive excitation while remaining the 
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network intact. Interestingly, the amplitudes of hyperpolarization were larger in input resistance-
altering SSI in cortical neurons compared to SSI in the hippocampus in which the input resistance did 
not change. Thus, the putative CB2R-mediated protective system might utilize a different pathway 
and be less effective in hippocampal cells in order to preserve the network. 
Further experimental work is necessary to directly address the question of whether SSI is linked to 
the neuroprotective effects described for CB2Rs. In vitro experiments should be performed to test the 
beneficial effects of neuronal CB2R activation for example in slice models of epilepsy and whether 
CB2R activation affects epileptic seizures or increases neuronal survival rates. 
Under physiological conditions, CB2R expression is very low in the CNS. However, in pathological 
conditions neuronal as well as microglial CB2R expression up-regulates quickly and profoundly 
proposing CB2Rs as a disease-associated target. CB2R expression is much higher in peripheral tissue, 
including immune cells and in spleen, compared to the CNS and its activation results in anti-
inflammatory and anti-nociceptive effects in these organs. Thus, systemic administration of CB2R-
targeting agents would activate both, central as well as peripheral CB2Rs. This dual activation might 
be beneficial in pathological conditions, since the neuroprotective properties of neuronal CB2R 
activation will be supported by central and peripheral immune mechanisms (Chen et al., 2017). 
Together with the lack of psychoactive effects upon CB2R activation and other CB1R activation-related 
side effects (Pertwee, 2012), these findings highlight that CB2Rs represent an excellent target for 
drug-discovery research for multiple pathological conditions. The description of the crystal structure 
for both CB1Rs and CB2Rs will enable structure-guided drug discovery to develop more selective 
compounds specifically targeting either CB2Rs alone or polypharmacologically both cannabinoid 
receptors to modulate the endocannabinoid system for therapeutic purposes. However, deeper 
understanding of the role of CB2Rs under physiological and pathological conditions is crucial to utilize 
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2-AG 2-arachnidonyl glycerol 
2-ALPI 2-arachidonoyl lysophosphatidyl inositol 
5-HT 5-hydroxytryptamine, serotonin 
AA Arachidonic acid 
ABHD /-Hydrolase domain containing enzyme 
AC Adenylyl cyclase 
ACSF Articifial cerebrospinal fluid 
ADP/ATP Adenosine di/triphosphate 
AEA Anandamide, N-arachidonoylethanolamine 
AHP Afterhyperpolarization 
AM-251 Inverse agonist at the CB1R 
AM-404 Cannabinoid reuptake inhibitor 
AMPAR -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor 
AP Action potential 
ATPase Adenosinetriphosphatase 
BAC-GFP Baculovirus vector based expression of green fluorescent protein 
BAPTA 1,2-bis(o-aminophenoxy)ethane-tetraacetic acid; Calcium chelator 
Bumetanide Inhibitor of the Na-K-Cl cotransporter (NKCC) 
CA1/3 Cornu Ammonis area 1/3 in the hippocampus 
cAMP Cyclic adenosine monophosphate 
Cariporide NA/H exchange inhibitor 
CB1/2R Cannabinoid receptor type 1/2 
cGMP Cyclic Guanosine monophosphate 
CGP55845 GABAB receptor antagonist 
CNR1/2 Gene encoding cannabinoid receptor type 1/2 
CNS Central nervous system 
Cox-2 Cyclooxygenase-2 
CP55,940 Synthetic CB1R and CB2R agonist 






DNDS Dinitro-disulfonic stilbene, Cl- channel inhibitor 
DSE/DSI Depolarization induced suppression of excitation/inhibition 
ER Endoplasmatic reticulum 
ERK Extracellular signal-regulated kinase 
FAAH Fatty acid amide hydrolase 
FS Fast spiking interneuron 
GABA -aminobutyric acid 
Gabazine SR-95531, GABAA receptor antagonist 
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GAD67 Glutamic acid decarboxylase; marker for GABAergic interneurons 
GDP/GTP Guanosine di/triphosphate 
GIRK G protein-coupled inwardly-rectifying K+ channel 
GP-AEA Glycerophospho-anandamide 
GPCR G protein-coupled receptor 
HU-308 CB2R selective agonist 
IP3 Inositol triphosphate 
IRBIT Inositol triphosphate receptor-binding protein 
JWH133 CB2R selective agonist 
KCC2 K+/Cl- transporter 
KO Knockout 
LPI Lysophosphatidylinositol 
LTD/LTP Long term depression/ potentiation 
LTS Low-threshold spiking interneurons 
Ly320135 CB1R inverse agonist 
Lyso-PI Lyso-phosphatidiylinositol 
Lyso-PLC/D Lyso-phospholipase C/D 
mACh Muscarinic acetylcholine receptor 
MAGL Monoacylglycerol lipase 
MAO Monoamine oxidase 
MAPK Mitogen-activated protein kinase 
mGluR Metabotropic glutamate receptor 
MSE/MSI Metabotropic suppression of excitation/inhibition 
NAAA N-acylethanolamine-hydrolysing acid amidase 
NADA N-arachnidonoyl dopamine 
NAPE N-arachidonoyl phosphatidylethanolamines 
NAPE-PLC/PLD N-arachidonoyl phosphatidylethanolamines specific phospholipase C/D 
NAT N-acyltransferase 
NBC Na+/bicarbonate  
NGS Normal goat serum 
NKCC Na+/ K+/Cl- transporter 
NMDA N-methyl-D-aspartate  
NMDG N-methyl-D-glucamin 
OLM Oriens-lacunosum moleculare  
OMDM-2 Cannabinoid reuptake inhibitor 
Ouabaine Na+/K+-ATPase inhibitor 
PBS Phosphate-buffered saline 
PC Pyramidal cell 
PGE2-GE Prostaglandin 2 glycerol ester 
PE Phosphatidyl-ethanolamines 
PI Phosphatidiylinositol 
PIP2/3 Phosphatidylinositol bi/triphosphate 
PKA/PKC Protein kinase A/C 
PLA/PLC Phospholipase A/C 
PTX Pertussis toxin, blocks Gi/o subunit signaling 
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RhoGEF Rho-guanine nucleotide exchange factors) 
Rin Input resistance 
Rotenone Inhibits complex I of the mitochondrial electron transport chain 
RSNPC Regular spiking non-pyramidal cells 
S0859 NBC blocker 
sACSF Sucrose based artificial cerebrospinal fluid 
SCH23390 GIRK channel blocker 
SERCA Sarcoplasmic/endoplasmic reticulum Ca2+ ATPase 
SR144258 CB2R inverse agonist 
SSI Slow self-inhibition 
THC (−)-trans-Δ⁹-tetrahydrocannabinol 
TRPV / TRPM Transient receptor potential ion channel; type vanilloid/melastatin  
VGCC Voltage-gated Ca2+ channel 
VIP Vasoactive intestinal peptide 
Vm Membrane potential 
VU0240551 KCC2 inhibitor 
WIN55,212-2 Synthetic cannabinoid receptor agonist 
WT Wild type 
Vm Membrane potential difference 
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